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Abstract 
Nearly 130 years have elapsed since the discovery of Mycobacterium 
tuberculosis (M.tb), the causative agent of tuberculosis, yet today it is estimated 
that 1 in every 3 of the worldʼs population is infected with this pathogen. In South 
Africa alone there were approximately 1000 new TB cases per 100 000 
population in 2007, ranking the country second in incidence rate, globally. 
Hence research into new vaccine strategies to control the epidemic is vital. 
Current vaccines under development are prophylactic and designed to boost 
pre-existing immunity induced by the only licensed TB vaccine, BCG. A new 
approach is the development of a post-infection vaccine aimed at inducing an 
immune response that prevents progression to TB disease whe  administered 
to individuals latently infected with M.tb. This vaccine would have a dramatic 
impact on the worldwide TB burden. 
 
Our objective was to address 2 areas in TB vaccinology, firstly a novel post-
infection TB vaccine strategy, and secondly, optimal measurement of vaccine-
induced responses using a new immunological assay.  
 
The aim of the first study was to investigate human T cell responses to 
antigens that have been associated with M.tb latency. Rv2660 and Rv2659 
were investigated, as these antigens are candidate antigens for a post-
infection vaccine based on findings from in vitro models of M.tb suggesting 
preferential expression during latency in vivo. No information exists on the 
immune response to these antigens in M.tb infected or TB diseased 
individuals. Hence, we investigated the immune recognition of Rv2660 and 
Rv2659 in these 2 groups, and further characterised the nature of these 
antigen-specific T cell responses. We observed that (i) these antigens are 
significantly more likely to be recognised during M.tb infection compared with 
TB disease as shown by measurement of soluble IFN-γ in response to the 
specific antigens, (ii) M.tb infected persons had greater Rv2660- and Rv2659-
specific CD4+ T cell proliferation and associated cytokine expression 
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compared, with TB diseased persons. We propose that Rv2660 and Rv2659 
may be candidates for incorporation into a post-infection vaccine. 
 
The aim of the second study was to determine whether antigen-specific T cell 
proliferation could reliably be identified through analysis of the intracellular 
expression of the nuclear protein, Ki67. Antigen-specific proliferation is a 
critical function of memory T cells that is often used as a measure of vaccine 
immunogenicity and T cell functional capacity. A Ki67 lymphoproliferation 
assay was optimised, and results compared to those from conventional 
assays that assess BrdU incorporation or Oregon Green (a CFSE derivative) 
dye dilution. The Ki67 assay proved to be more sensitive than BrdU 
incorporation for detection of proliferating cells, whereas sensitivity was 
similar to the dye dilution of Oregon Green. Overall, our data suggest that 
intracellular Ki67 expression provides a specific, quantitative and reproducible 
measure of antigen-specific T cell proliferation in vitro.  Importantly, the Ki67 
assay requires small volumes of blood, and is a very practical and efficient 
assay for measuring vaccine induced T cell responses. 
 
In conclusion, findings presented in this thesis will contribute significantly to 
the field of tuberculosis vaccinology. 
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Chapter 1: Literature Review 
 
1.1 The immune system 
The human immune system is constantly challenged by a variety of 
pathogenic microbes and foreign substances. A complex array of 
mechanisms evolved to enable the recognition and protection of the host from 
pathogenic microorganisms and viruses. This response is typically 
characterised by differentiation of foreign (or ʻnon-selfʼ) from ʻselfʼ elements, 
resulting in mechanisms for elimination of foreign material, while not 
compromising host tissue. This complex process is executed by two arms of 
the immune system: the innate immune response and the adaptive immune 
response. For the successful clearance of an invading pathogen, the immune 
system must act promptly and initiate these responses through involvement of 
a diverse array of leukocytes and their soluble secretory products (Figure 1.1) 
(Janeway CA, 2008; Chaplin, 2010). 
 
1.1.2 The Innate Immune System 
The innate immune response is non-specific and provides the first line of 
defence against foreign invaders. Professional phagocytic cells, which include 
monocytes, neutrophils, and macrophages, possess a primitive recognition 
system. Since the innate immune response makes use of invariant recognition 
molecules expressed on a large number of cells, it reacts swiftly to an 
invading pathogen. These innate cells are rapidly recruited to the site of 
infection by chemotactic signals (Janeway CA, 2008; Chaplin, 2010). 
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Figure 1.1 The main components of the innate and adaptive immune systems. The 
innate immune response functions as the first line of defenc  against infection. The adaptive 
immune response is slower to develop, but manifests as increased antigenic specificity and 
memory (From Tennant DA et al. Nature Reviews Cancer 2004). 
 
Neutrophils accumulate at sites of in ection to phagocytose and degrade 
microbes by producing reactive oxygen species (ROS) that are cytotoxic to 
pathogens. Monocytes and macrophage are highly phagocytic and are 
mobilized shortly after neutrophil recruitment to the inflammatory site to 
produce nitric oxide (NO), which is a critical effector molecule for killing 
microbial pathogens (Janeway CA, 2008).  
 
Antigen presenting cells (APCs) such as dendritic cells (DC) and 
macrophages recognize pathogens via the expression of pathogen associated 
molecular patterns (PAMPs), which bind to pattern recognition receptors on or 
in the cells (PRRs). Upon engagement, the APCs ingest the microorganism, 
become activated, and release factors to enhance and instruct the 
subsequent adaptive immune response. Activated APCs migrate from the site 
of infection to regional lymph nodes where processed antigen (Ag) is 
presented to cognate T cells as peptides primarily via major histocompatibility 
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complex (MHC) class I or II molecules (Janeway CA, 2008; Iwasaki and 
Medzhitov, 2010). 
 
1.1.3 The Adaptive Immune System 
If the innate response is unsuccessful in eliminating the infection rapidly, the 
adaptive immune response is primed for pathogen control (Janeway CA, 
2008). The hallmark of the adaptive immune response is antigen specificity 
and the capacity to develop long-lived memory, which would allow for a swift 
and efficient adaptive response upon secondary encounter with the antigen/ 
pathogen. The adaptive immune response is mediated by T and B 
lymphocytes, which develop in the thymus and bone marrow, respectively, 
and exit these primary lymphoid tissues as naïve lymphocytes.  
 
T lymphocytes represent the primary effector cells of the cell-mediated 
immune (CMI) response and function primarily by secreting effector molecules 
and mediators. CD4+ T cells, including T helper (TH) 1, TH2 TH17 and 
regulatory T cell (Treg) subsets, recognise peptides presented by MHC II on 
APCs, and in addition to having effector function, have a critical role in 
coordinating or regulating the ensuing immune response. CD8+ T cells 
recognise peptides bound to MHC I, and primarily have a cytotoxic function 
(McCullough and Summerfield, 2005; Iwasaki and Medzhitov, 2010). Other T 
cell subsets, such as gamma-delta T cells and NK T cells, may also play an 
important role in the adaptive response to microorganisms. 
 
Naïve T cells circulate between the blood and secondary lymphoid tissue until 
encountering cognate antigen presented by APCs. For an antigen-specific T 
cell to become activated, 2 critical signals must be received. Firstly, the T cell 
receptor (TCR) engages the cognate peptide-MHC complex, and secondly, 
co-stimulation is provided via interaction between CD28 on the T cell and 
CD80 (B7.1) and CD86 (B7.2) on the APC. Other signals from the APC and 
the environment play a critical role in determining which of multiple distinct 
phenotypic and functional cells the naïve cell differentiates into. The 
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differentiation fate of these naïve T cells is largely decided by the cytokine 
milieu present, and may ultimately lead to a differentiation into TH1 or TH2 or 
TH17 or Treg cells (Figure 1.2) (Dong 2006, Deenick et al 2007). The innate 
cell cytokine IL-12 activates the transcription factor STAT-4, which drives the 
differentiation of CD4+ T cells into TH1 cells, which typically produce the 
cytokines IFN-γ, TNF-α and IL-2, and provide protection against intracellular 
pathogens such as viruses and bacteria. The induction of TH2 cells is initiated 
by IL-4-mediated activation of STAT-6, which typically produce the cytokines 
IL-4, IL-5 and IL-13, and provide protection against extracellular pathogens 
and parasites. CD8+ T cells on the other hand, primarily kill pathogen-infected 
cells by releasing cytotoxic granules such as perforin and granzymes. There 
is overlap between CD4+ and CD8+ T cell function, as both subsets may 
produce cytokines or have cytotoxic function (Chaplin, 2010). 
 
Two additional subsets of T cells have recently been described, TH17 and 
regulatory T cells (Tregs). In the presence of transforming growth factor β 
(TGF-β) and interleukin 6 (IL-6), naïve CD4+ T cells differentiate into TH17 
cells, which produce interleukin 17 (IL-17). (Many other cytokine signals that 
results in TH17 differentiation have also been described.) TH17 cells mainly 
produce the pro-inflammatory cytokine IL-17, which has been implicated in the 
induction of autoimmun  diseases, and mediates a protective role against 
extracellular bacteria (Weaver et al., 2007). It has been shown that IL-23 is 
important in maintaining TH17 cells and hence regulating the expression of IL-
17 (Harrington et al., 2006). Tregs suppress effector immune responses and 
immune-mediated pathology, thereby maintaining immune system 
homeostasis. These cells express FOXP3 and high levels of CD25 on the 
surface, and in vitro experiments indicate that TGF-β and IL-10 are partly 
involved in the immunosuppressive activity of this population (Wan, 2010).  
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Figure 1.2 Overview of the molecular requirements for T cell differentiation and the 
functional roles of the subsets. (From Deenick EK et al ,Immunology Cell Biology 2007). 
 
B lymphocytes represent the primary effector cells of the humoral immune 
response, and can directly recognise foreign material or antigen via surface 
immunoglobin receptors. Once a naïve B cell encounters antigen, the cell 
becomes activated, clonally expands, and generates antigen-specific 
antibodies. Activated B cells may differentiate into plasma cells or memory B 
cells. Plasma cells refer to a population of terminally differentiated B cells with 
the capacity to produce and release large amounts of antibodies. These 
antibodies may play a role in the opsonisation of pathogens, which facilitates 
enhanced phagocytosis, or may neutralise pathogens by preventing cellular 
infection. Memory B cells, on the other hand, are long-lived B cells that 
expand swiftly when restimulated with the same antigen, and mediate rapid 
effector function (Janeway CA, 2008).  
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B and TH cells are in continuous interaction with each other. B cells can be 
activated in either a TH dependent or independent manner. Upon encounter 
with antigen B cells under the influence of cytokines produced by TH cells 
develop into plasma cells that secret a distinct class of antibodies, this 
maturation of B cells is largely governed by TH2 cells. Antibody class 
switching however; is influenced by different TH cells, with TH1 cells favouring 
the production of opsonising antibodies and TH2 cells favouring the production 
of neutralizing antibodies. This interaction is one of many which indicate that 
multiple cellular populations are involved in eliciting a specific immune 
response. 
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1.2 Tuberculosis  
The pathogen identified to be the causative agent of tuberculosis (TB) 
disease, Mycobacterium tuberculosis (M.tb), was initially described by Robert 
Koch in 1882. It has subsequently been characterized as a gram-positive, 
slow growing, facultative intracellular pathogen (Manganelli et al., 1999). 
Along with other members of the Mycobacterium genus, M.tb has a unique 
waxy cell wall of which the majority of the constituents are mycolic acids, 
which make up more than 50% of the bacteriaʼs dry weight (Brennan and 
Nikaido, 1995). This allows the bacteria to retain basic dyes in the presence of 
acid alcohols, hence their classical acid fastness (Allen, 1992). 
 
1.2.1 Epidemiology 
TB is a major global health concern and is responsible for more deaths than 
any other curable infectious disease. Epidemiologists estimate that 2 billion of 
the worldʼs population is latently infected with M.tb, and that 9.27 million new 
TB cases occurred in 2007 alone (WHO report, 2009). The majority of these 
patients were from South East Asia and Sub-Saharan Africa. In 2007, the 
incidence rate in Sub-Saharan Africa was 325 cases per 100,000 people, 
which was twice the rate of South East Asia. The statistics are far more 
alarming in South Africa, which has an incidence rate of approximately 1,000 
cases per 100,000 people per annum (Figure 1.3). 
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Figure 1.3 The global distribution pattern of new TB cases in 2007 indicates that 
developing countries are most affected (Map derived from the WHO Report, Global 
tuberculosis control-surveillance, planning, financing 2007). 
 
According to the global distribution pattern, the vast majority of new TB cases 
occur in developing countries, a phenomenon strongly associated with human 
immunodeficiency virus (HIV) co-infection (Figure. 1.4). Whereas the lifetime 
risk of developing TB disease following infection is 10% in HIV-uninfected 
persons, the annual risk of developing TB is 10% in individuals co-infected 
with HIV. Among other factors, depletion of CD4 T cells are likely to be 
responsible, as these cells are critical for protection against TB.  HIV-infected 
persons demonstrate both increased rates of reactivation of latent TB and 
more rapid progression to active disease. TB is currently the major cause of 
mortality amongst HIV infected individuals (Skeiky and Sadoff, 2006). 
 
The eradication of TB seems even more challenging considering the fact that 
some strains are resistant to anti-TB drugs. These include the multidrug 
resistant (MDR) bacilli, resistant to at least isoniazid and rifampicin, and 
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extensively drug resistant (XDR) bacilli, resistant to isoniazid, rifampicin, and 
at least 3 classes of second-line drugs. MDR and XDR in particular is of major 
concern since treatment options are limited and expensive, while outcomes 
are poor, particularly in HIV-infected persons (Gandhi et al., 2006). The World 
Health Organisation (WHO) has classified 27 countries, including South Africa 
as global priority settings for the improved management of MDR-TB.  
Figure 1.4. Fifteen countries with the highest estimated tuberculosis incidence rates 
per capita in 2007. Grey bars indicate tuberculosis incidence for all ages and the orange 
bars indicate the corresponding co-infection with HIV among adults aged 15-49 years. (Graph 
derived from the WHO Report, Global tuberculosis control-surveillance, planning, financing 
2007). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 10 
1.2.2 Host pathogen interaction  
In order to understand the success of M.tb infection and to develop effective 
intervention strategies, it is critical to gain insight into both the pathogenesis of 
infection and disease, and the host immune response to control the infection. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Different outcomes of M. tuberculosis infection and underlying immune 
mechanisms. (From Kaufmann, Nature Medicine. Reviews, 2005) 
 
The main route of infection with M.tb is via the aerosol route, i.e., inhalation of 
infected airborne micro-droplets. Once the pathogen reaches the lungs, it is 
immediately recognised and phagocytosed by alveolar macrophages, 
resulting in sequestration within a phagosome (Russell, 2001). The bacterium 
is recognised by macrophages through mainly toll-like and C-type lectin 
receptors (Akira et al., 2006; Dulphy et al., 2007). These receptors recognise 
PAMPs, which are invariant molecular structures expressed by pathogens. 
Following Infection the immune response mounted by the host can result in 
differential outcomes, which are depicted in Figure 1.5. Firstly, the infection 
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can be eliminated by the host immediately after inhalation; it is difficult to 
know how often this occurs, while the mechanisms underlying this clearance 
have not been fully elucidated (Bhatt and Salgame, 2007). Secondly, M.tb 
bacilli may be contained by the immune response within a specialised 
pathophysiological structure in the lung, called a granuloma. The pathogen 
may remain quiescent within granulomas for many years, while the host 
remains clinically asymptomatic; this is referred to as latent TB infection 
(LTBI), and has occurred in up to one third of the worldʼs population (WHO 
report, 2009). Thirdly, infection can lead to TB disease early after infection, or 
much later in life. Disease is likely to manifest in genetically susceptible 
individuals, or in persons with immune deficiency, which may be relative (e.g., 
very young or old age) or overt (e.g., HIV infection). HIV infection increases 
the risk of developing TB disease 800-fold (Russell, 2001; Kaufmann et al., 
2005). In the diseased individual, M.tb had escaped containment in the 
granuloma, resulting in local dissemination to the rest of the lungs, where the 
inflammatory response subsequently caused local symptoms such as a cough 
with sputum production, or systemic symptoms such as weight loss, severe 
wasting disease, night sweats and fever (Kaufmann et al., 2010). 
 
1.2.3 Latent M.tb infection 
As with any manifestation of TB, latency is the result of a dynamic interaction 
between host and pathogen. A distinctive feature of M.tb bacilli is the ability to 
persist in a latent state within a granuloma. During this latent M.tb infection 
there are no signs or symptoms of the disease and the host is unable to 
transmit the infection. The significance of latent TB infection is that it does not 
remain latent in all individuals and they represent a reservoir of M.tb with the 
potential for reactivation and causing disease (Ehlers, 2009; Lin and Flynn, 
2010).  
 
Two models of latency have been proposed: (i) A programmed response of 
M.tb to the host environment induces a metabolic adaptation in the bacterium 
for long-term, symbiotic survival, and (ii) The host immune response drives 
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the bacterium into this alternate metabolic state, allowing dormancy or slow 
replication only (Hanekom and Ernst, 2008). 
 
It was initially postulated that M.tb bacilli are actively replicating during TB 
disease and in a non-replicating state during clinical latency. However, there 
is now growing evidence from state-of-the-art medical imaging such as 
computed tomography that during latency, some M.tb bacilli within granuloma 
lesions remain metabolically active. This suggests that similar to active TB, 
there may be a range of infection states under the umbrella of latency, making 
this a more dynamic process than previously imagined. This implies that LTBI 
should be studied further to understand the dynamic range, and which 
infection state would put a person at risk of future disease (Barry et al., 2009; 
Ehlers, 2009).  
 
(i) Diagnosis of latent M.tb infection 
Current diagnosis of LTBI relies on detection of immunological memory to 
M.tb antigens. A classical diagnostic test such as the tuberculin skin test 
(TST) can be used to diagnose M.tb infection: delayed type hypersensitivity 
response is measured 48–72 hours after intradermal injection of purified-
protein derivative (PPD). A limitation of the TST is that interpretation of a 
result is often complicated by the detection of cross-reactive immune 
responses in individuals vaccinated with Mycobacterium bovis bacillus 
Calmette-Guérin (BCG) or exposed to environmental mycobacteria (Arend et 
al., 2001; Gallant et al., 2009). A recent diagnostic test, the QuantiFERON®-
TB Gold In-Tube (QFT™) detects IFN-γ release by a memory T cell response 
to the M.tb–specific antigens, early secretory antigen-6 (ESAT-6), culture 
filtrate protein-10 (CFP-10) and TB7.7 (Mori et al., 2004). Although this test 
has shown to be very useful in low TB incidence areas, current evidence does 
not support superior performance over the TST in settings of high TB 
incidence (Kariminia et al., 2009). 
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1.3 Immunity to tuberculosis 
M.tb has evolved ways to adapt to the hostile host immunity in order to 
survive. As mentioned above, after inhalation, M.tb is engulfed by alveolar 
macrophages and DCs, which migrate to the draining lymph nodes where 
they present mycobacterial antigens to cognate T cells (Chan and Flynn, 
2004).  
 
1.3.1 Cellular immunity to M.tb 
There is extensive evidence to support a central role of TH1 immunity in host 
protection against M.tb infection. Mouse studies and evidence obtained from 
individuals susceptible to mycobacterial infection reveal that the IL-12/IFN-γ 
pathway is indispensable for protection against infection (Altare et al., 1998; 
Cooper et al., 1993; Cooper et al., 1997; Flynn et al., 1993; Jouanguy et al., 
1996; Newport et al., 1996). Multiple components of the immune system act in 
concert to induce an optimum response including T cells, activated 
macrophages, and cytokines such as interferon-gamma (IFN-γ), interleukin-2 
(IL-2) and tumor necrosis factor (TNF-α). The macrophage-activating and 
“protective” TH1 phenotype is driven by the local release of interleukin-12 (IL-
12) from infected cells (Ladel et al., 1997). 
 
(i) Macrophages as the effectors of TH1 immunity 
The macrophage is central to the control of M.tb infection. M.tb multiply in 
resting macrophages, but activation of infected macrophages with IFN-γ 
results in induction of mycobacteriostatic or mycobacteriocidal states in vitro 
(Flesch and Kaufmann, 1987). TNF-α and IFN-γ act synergistically to activate 
macrophages, and subsequently induce production of reactive nitrogen 
intermediates (RNIs), one of the antimicrobial defence mechanisms (Ding et 
al., 1988). Nitric oxide (NO) is generated from L-arginine via the enzymatic 
action of the inducible isoform of nitric oxide synthase (NOS2) (Ding et al., 
1988) and its importance in protective immunity was confirmed in studies 
where mice deficient of NOS2 activity were shown to be susceptible to M.tb 
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infection (Chan et al., 1995; Flynn et al., 1998; MacMicking et al., 1997; 
Scanga et al., 2001). The relevance of this mechanism in human infection 
remains controversial: however, there are reports of NOS2 induction and/or 
RNI production by human macrophages (Bonecini-Almeida et al., 1998; 
Nicholson et al., 1996; Rockett et al., 1998). Moreover, production of reactive 
oxygen species (ROS) is required for optimum host protection against M.tb. 
Mice incapable of expressing NADPH-oxidase, and therefore no ROS, were 
shown to be more susceptible to M.tb compared with WT mice (Cooper et al., 
2000). Another mechanism of M.tb elimination is a vitamin-D dependent 
pathway which leads to the induction of the antimicrobial peptide, cathelicidin, 
which results in the killing of M.tb (Liu et al., 2007).  
 
(ii) CD4+ T cells 
TH1 cells 
It is well established that CD4+ T cells are essential for protective immunity 
against M.tb. AIDS patients with low CD4+ T cell counts are much more likely 
to develop active TB disease than HIV-uninfected individuals, providing 
evidence of the importance of CD4+ T cells in anti-TB immunity (Aaron et al., 
2004). Mice deficient in CD4+ T cells have diminished ability to control 
infection further indicating the importance of this subset in protective immunity 
against M.tb (Caruso et al., 1999; Tascon et al., 1998). Importantly, Feng et 
al. showed that the adoptive transfer of CD4+ T cells conferred protection to 
M.tb in RAG mice, which are deficient in B and T cells (Feng and Britton, 
2000).  
 
IFN-γ produced by CD4+ T cells is central for the activation of anti-
mycobacterial macrophages as described above (Cooper et al., 1993). TNF-α 
on the other hand, acts synergistically with IFN-γ to fully activate 
macrophages, and for the initiation and maintenance of granulomas (Cooper 
et al., 1993). TNF gene deletion (Bean et al., 1999) and TNF neutralization 
studies (Eriks and Emerson, 1997; Kindler et al., 1989) have demonstrated 
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that TNF plays a critical role in protective immunity against M.tb infection. In 
the absence of TNF, mice challenged with either avirulent M. bovis or virulent 
M.tb were shown to succumb to infection more rapidly, compared with wild 
type mice (Bean et al., 1999; Jacobs et al., 2000). Although IL‑2 has little 
direct effector function, the cytokine promotes expansion of CD4+ and CD8+ T 
cells; hence, IL-2 serves to amplify effector T‑cell responses. In addition, IL‑2 
produced by T cells can enhance natural killer cell activity that could 
contribute to the early control of infection (Seder et al., 2008).  
 
So-called “polyfunctional” CD4+ T cells, which co-express the cytokines IFN-γ, 
TNF-α and IL-2, have recently achieved prominence in the immunological 
literature. Darrah et al showed in mice that following primary infection with 
another intracellular pathogen, Leishmania major, or after vaccination against 
this organism, the generation of polyfunctional T cells that secrete IFN-γ, IL‑2 
and TNF strongly correlated with protection against subsequent challenge. 
This study emphasized that measuring the magnitude of IFN-γ producing 
CD4+ T cells alone was not sufficient to predict protection (Makedonas and 
Betts, 2006; Darrah et al., 2007; Seder et al., 2008). In addition, it has been 
shown in a murine TB model that more polyfunctional cells at the site of 
infection associated with a more protective immune response against TB 
(Forbes et al., 2008).  
 
TH17 cells  
TH17 cells have been reported by several groups to mediate a role during M.tb 
infection. Immunization of mice with a novel vaccine comprising an 
immunodominant epitope derived from ESAT-6 resulted in significant 
protection of vaccinated mice upon M.tb infection. This protection was shown 
to be mediated, in part, by specific TH17 cells in the lung, which subsequently 
induced recruitment of IFN-γ producing TH1 cells, through up-regulation of the 
chemokines CXCL9, CXCL10, and CXCL11(Wozniak et al., 2006; Khader et 
al., 2007). A study by Scriba et al. reported that mycobacteria-specific TH17 
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cells were present in healthy M.tb-exposed and TB diseased patients; 
however, TH17 frequencies were lower in the latter group, indicating a 
potential protective role against TB disease development (Scriba et al., 2008). 
Further studies are required to understand the role of this pro-inflammatory 
cytokine in protection against TB for interventions such as novel TB vaccines. 
 
Regulatory T cells  
Jaron et al. have shown that depletion of Tregs in BCG vaccinated mice 
results in, a reduction of the bacterial burden after challenge with M.tb., 
indicating that Tregs inhibit the M.tb-specific effector response and have a 
negative impact on immune control (Jaron et al., 2008). A clinical study 
investigating the role of Tregs showed that TB diseased patients had higher 
frequencies of Tregs in peripheral blood compared to healthy uninfected 
individuals. Furthermore, ex vivo depletion of Tregs from PBMC resulted in 
increased numbers of ESAT-6- and CFP-10–specific IFN-γ producing T cells. 
This may indicate that the expanded Treg population in TB patients may 
contribute to suppression of TH1 immunity (Guyot-Revol et al., 2006). The role 
of Tregs may be explained by a recent study by Shafiani et al, who used a 
murine model to demonstrate that even small numbers of M.tb-specific Tregs 
might actually impair immune protection by delaying the priming of M.tb-
specific effector T cells, and hence their accumulation at the primary site of 
infection, the lung. The delay in the recruitment of M.tb-specific effector T cells 
in the lung results in a prolonged bacterial expansion and may explain the 
higher bacterial burden observed in mice injected with M.tb-specific Tregs 
(Shafiani et al., 2010). 
 
(iii) CD8+ T cells  
M.tb antigens can be presented to CD8+ T cells primarily via the MHC–I 
pathway. Evidence from several studies has confirmed the importance of 
CD8+ T cells in the immune responses against M.tb. A study in non-human 
primates showed that depletion of CD8+ T cells compromised BCG vaccine-
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induced immune control of M.tb replication in the animals, and this led to a 
significant decrease in the vaccine-induced immunity against TB (Chen et al., 
2009). Experiments carried out by Flynn et al. showed that mice deficient in 
β2-microglobulin, which therefore lack MHC class I molecules and 
consequently fail to develop functional CD8+ T cells, were more susceptible to 
M.tb (Flynn et al., 1992). Although M.tb resides within phagosomes, several 
mechanisms have been proposed to explain how the organism could gain 
access to the cytoplasm, leading to presentation of mycobacterial peptides via 
the MHC-I pathway. Myrvik and colleagues suggested that M.tb was able to 
perforate the phagosomal membrane in order to use the nutrients in the 
cytosol. It was postulated that M.tb in the cytoplasm would result in enhanced 
MHC class I presentation to CD8+ T cells (Myrvik et al., 1984). CD8+ T cells 
may also be activated through cross-presentation of antigens (Schaible et al., 
2003). Macrophages infected with M.tb undergo apoptosis and vesicles 
containing M.tb antigens can then be taken up by bystander DC, which are 
able to present the antigens via the MHC-I pathway, leading to the priming of 
CD8+ T cells. 
 
Effector functions of CD8+ T cells include amongst others, production of IFN-γ 
and TNF-α (Caruso et al., 1999; Scanga et al., 2000), which induce 
macrophage activation, as well as lysis of infected cells. CD8+ T cells lyse 
infected cells by releasing perforin which forms pores on the cell membrane 
surface (Stenger et al., 1997). This reduces the pool of infected cells and 
causes the release of bacteria, which can be killed more efficiently by 
activated macrophages. Alternatively, CD8+ T cells may directly kill the 
intracellular bacteria directly by releasing granulysin (Stenger et al., 1998), 
however this happens only in the presence of perforin, which allows the 
granulysin to gain access to the cell. Experiments by Stenger et al. 
demonstrated a decrease in viability of intracellular mycobacteria when 
infected macrophages were incubated with perforin and granulysin (Stenger et 
al., 1997). 
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1.3.2 Humoral immunity to M.tb 
Many questions regarding the role of B cells during M.tb infection remains 
unanswered. Since M.tb resides within phagosomes, the dogma has been that 
only cell-mediated responses are important in protective immunity against 
M.tb. However, BCG vaccination induces anti-lipoarabinomannan (LAM) IgG1 
(de Valliere et al., 2005), and administration of anti-LAM antibodies results in 
increased survival of mice after challenge with M.tb (Teitelbaum et al., 1998). 
Furthermore, anti-mycobacterial antibodies were shown to enhance innate 
immunity, by allowing improved uptake and subsequent killing of 
mycobacteria by macrophages in the presence of specific antibodies. 
Moreover, coating of mycobacteria with specific antibodies resulted in more 
effective processing and presentation by DCs via Fc receptors resulting in an 
enhanced ability to stimulate CD4+ and CD8+ T cells (de Valliere et al., 2005). 
Presumably, anti-TB antibodies mediate a more relevant role when M.tb is 
extracellular, e.g., upon lysis of infected macrophages, and during 
dissemination. Antibodies may also play an indirect role in controlling 
inflammation caused by infection with M.tb. Maglione et al found that adoptive 
transfer of B cells resolved the inflammatory exacerbation observed in B-cell-
deficient mice upon airborne challenge with M.tb (Maglione et al., 2007). 
Antibodies may therefore have a variety of protective effects during infection 
with intracellular pathogens (Maglione and Chan, 2009). 
 
It is important to note that a complex orchestrated interaction of multiple cell 
types, including innate cells and T cell subsets, in balance, is likely to be 
important for optimal immunity against M.tb (Kaufmann et al., 2005; Hanekom 
et al., 2007). 
 
1.4 Vaccination Strategies against Mycobacterium tuberculosis  
1.4.1 Current strategies 
There is an urgent need for an effective vaccine to prevent TB disease; this is 
likely the most sustainable solution to control the TB epidemic. BCG is the 
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only licensed vaccine currently available. BCG is an attenuated form of 
Mycobacterium bovis, which was generated after multiple in vitro passages of 
the organism (Reece and Kaufmann, 2008). Despite being safe and currently 
the most widely used vaccine in the world, its efficacy remains variable (Fine, 
1995; Behr, 2002). BCG provides approximately 80% protection against 
severe forms of TB in infants, such as meningitis and miliary disease, but 
confers variable protection against pulmonary TB disease at all ages. It is 
estimated that the efficacy of BCG to protect adults against lung TB disease 
varies between 0 and 80% (Colditz et al., 1994; Brandt et al., 2002). 
 
One of the main reasons accounting for the variability of BCG may be that 
pre-exposure to environmental mycobacteria may induce immunity that would 
clear BCG before it can induce an immune response. It has been shown in 
mice that exposure to environmental mycobacteria can result in cross-reactive 
immunity, which leads to more rapid clearance of BCG upon vaccination and 
reduced immunogenicity as a consequence (Brandt et al., 2002). The 
discrepancies in BCG efficacy may also be explained by strain variability 
(Behr, 2002), as significant differences in the genome of different BCG strains 
have been described (Brosch et al., 2007), which may influence 
immunogenicity (Aguirre-Blanco et al., 2007) and virulence (Kroger et al., 
1995). The variable efficacy of BCG may also be attributable to genetic 
differences in host populations (Fine, 1998). 
 
1.4.2 New vaccination approaches 
Given the variable efficacy of BCG in providing protection against TB disease, 
intensive research is being carried out to develop an improved vaccine or 
improved vaccination strategy. New vaccines would have to be at least as 
effective as BCG (Reece and Kaufmann, 2008). Current vaccines under 
development are designed to either improve BCG or boost immunity induced 
by BCG. These could be combined in heterologous prime-boost vaccination 
strategies (McShane et al., 2004). The prime vaccine is likely to remain BCG 
or will perhaps be replaced with a modified BCG to become more effective, or 
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even an attenuated M.tb. It is likely that this vaccine will continue to be 
administered at birth. It is proposed that a different (i.e., heterologous) boost 
vaccine will be administered at a later time point. This vaccine will comprise 
antigens present in BCG and M.tb. These vaccines are designed as 
prophylactic (pre-exposure) vaccines and, hence, are aimed at stimulating an 
immune response that controls subsequent infection more effectively than the 
immune response stimulated during natural infection. It is probable that these 
vaccines might prolong the duration of asymptomatic infection, thus delaying 
disease outbreak due to reactivation or re-infection. (Brennan et al., 2007; 
Barker et al., 2009). Post-infection vaccines are also in the pipeline and these 
will be aimed at LTBI individuals to prevent progression to TB disease. A post-
infection vaccine will contain proteins that are primarily expressed during the 
latent stage of infection, and is likely to boost the immune response induced 
after natural infection with M.tb (Lambert et al., 2009). The addition of latency 
associated antigens to well-established prophylactic vaccines (i.e., the 
vaccine candidates under clinical testing today) have been suggested as the 
basis for a future generation of multi-stage TB vaccines with activity against 
all stages of infection (Andersen, 2007a).  
 
(i) Prophylactic vaccines 
(A) Recombinant BCG (rBCG) and attenuated M.tb strains are two 
approaches being explored to replace the standard BCG with an improved 
priming vaccine. These vaccines are based on strains of BCG currently in 
use, or are derived from attenuation of M.tb through deletion of genes 
associated with virulence (Lambert et al., 2009). rBCG30 is an example of a 
new TB vaccine which aims to induce a more potent immune response by 
overexpressing a key M.tb antigen (Rao et al., 2003). This rBCG vaccine, 
overexpressing the immunodominant Ag85B controlled a virulent M.tb 
challenge more effectively than mice immunized with normal BCG, had lesser 
pathology in lungs and spleens, and survived longer (Horwitz et al., 2000; 
Horwitz and Harth, 2003). Importantly, rBCG30 has limited replication in vivo 
in SCID (severe combined immune deficiency) compared to parental BCG, 
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which may translate to better safety for administration to HIV infected 
individuals (Tullius et al., 2008; Lambert et al., 2009). 
 
A different approach involves the use of a mutant strain of Mycobacterium 
bovis. The ∆ ureC hly+ rBCG (VPM1002) is a urease C deficient mutant 
expressing the listeriolysin gene (Grode et al., 2005). The bacterium is unable 
to inhibit phagolysosome formation, given that urease C is important in 
neutralising phagosome acidity, which is critical for lysosome fusion (Schaible 
et al., 1998). Lysteriolysin, which originates from the organism Listeria 
monocytogenes, induces pore formation and therefore allows the organism to 
escape from the phagosome into the cytoplasm (Conradt et al., 1999; Grode 
et al., 2005). It was postulated that BCG in the cytoplasm would result in 
enhanced MHC class I presentation to CD8 T cells. Subsequent preclinical 
studies in mice, guinea pigs and non-human primates have demonstrated a 
superior CD8 T cell mediated response when ∆ureC hly+ rBCG was compared 
with normal BCG. In addition the rBCG showed greater safety and efficacy 
against an aerosol infection with M.tb than the parent BCG strain in 
immunodeficient mice (Grode et al., 2005), 
 
Several other live attenuated candidates are also being assessed in 
preclinical studies. MTBVAC01 is a live attenuated M.tb that is a double 
mutant deficient in the virulence genes phoP and fadD26 (Perez et al., 2001; 
Soto et al., 2004). This vaccine has proven to be safe in severe combined 
immunodeficiency (SCID) mice and has conferred better protective efficacy, 
compared with BCG (Martin et al., 2006). Verreck, et al, in a non-human 
primate model have shown that MTBVAC01 was well tolerated and afforded 
protection against challenge with a virulent M.tb (Verreck et al., 2009). A 
major concern for attenuated M.tb vaccines is the potential to revert to a 
virulent form hence these vaccines are required to undergo rigorous safety 
testing.  
 
(B) Viral vectored vaccines containing antigens present in both BCG and M.tb, 
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and are aimed at enhancing immunity induced by BCG. Live vectors such as 
Adenovirus (Ad) and modified Vaccinia Ankara (MVA) have been engineered 
to be non-replicating and to deliver relevant antigens into the host. Pre-
exposure to environmental mycobacteria may affect the efficacy of whole 
mycobacterial vaccines like BCG or attenuated M. tuberculosis (Fine, 1998); 
live viral vectors remain an ideal alternative in such settings. Two examples of 
viral vectored vaccines include the MVA85A and Areas402 vaccines, the 
backbone of which are replication-deficient viruses. These vaccines contain 
antigens expressed by both BCG and M.tb and are aimed at enhancing 
immunity induced by BCG, which is given at birth.  
 
MVA85A comprises modified vaccinia Ankara and antigen 85A (McShane et 
al., 2004). Ag85A and B are part of the immunodominant Ag85 complex and 
are involved in mycobacterial cell wall synthesis (Belisle et al., 1997). 
MVA85A was the first viral vectored TB vaccine to be tested in humans. The 
clinical trials in adolescents and adults have shown that MVA85A is a safe 
vaccine that induces durable T cell responses, including an IFN-γ+TNF-α+IL-
2+, polyfunctional T cell response (McShane et al., 2004; Sander et al., 2009). 
MVA85A is undergoing multiple phase I/II trials in Africa, including trials in HIV 
infected patients and a phase IIb trial in infants (Lambert et al., 2009). Aeras-
402 comprises an Adenovirus, serotype 35, that expresses a fusion protein of 
Ag85A, Ag85B and TB10.4 (Hussey et al., 2007). TB10.4 is a member of the 
ESAT-6 family of proteins and has been shown to be immunogenic (Skjot et 
al., 2002). The vaccine is in several Phase I/IIa trials in Africa, USA and 
Europe. Thus far, Aeras-402 has been shown to be safe, and able to induce a 
polyfunctional CD4 T cell response as well as a durable and robust CD8 T cell 
response in healthy adults (Abel et al., 2010). One concern is that previous 
natural exposure to a cross-reactive strain of adenovirus may hinder 
responses to adenovirus-based vaccines. Since the Ad35 serotype has a low 
prevalence, ranging from 3%-5% in developed countries and 20% in Africa, 
this vaccine may escape this limitation (Lambert et al., 2009). 
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(C) Subunit vaccines are designed to contain recombinant proteins that are 
administered with a TH1-inducing adjuvant. Ideally, a subunit vaccine would 
comprise broadly recognised T cell epitopes to ensure the broad coverage of 
different populations (Weinrich Olsen et al., 2001; Skeiky et al., 2004). 
Examples of subunit vaccines include the Hybrid 1(H1) and the Mtb72F (M72) 
vaccines. H1 contains a fusion protein of Ag85B and ESAT-6 and the 
adjuvant IC31. Both Ag85B and ESAT-6 are strongly recognised by the host 
immune system during primary infection and have been shown to be 
protective when used as vaccines in animal models with IC31, a combination 
of a leucine-rich peptide named KLK and a synthetic oligonucleotide, named 
ODN1a (Weinrich Olsen et al., 2001; Aagaard et al., 2009). M72 contains the 
antigens Mtb32 and 39 expressed as a recombinant fusion polyprotein, 
together with the adjuvant ASO1E. This vaccine has been shown to induce 
robust T cell and antibody responses in healthy adults, (Von Eschen et al., 
2009) and to protect mice, guinea pigs and nonhuman primates against 
challenge with virulent M.tb (Skeiky et al., 2004). Several Phase I and II 
clinical trials have been completed and results indicate cell mediated 
responses induced by M72 persisted for at least 6 months post vaccination 
(Lambert et al., 2009) 
 
(ii) Post-infection vaccine  
Recent TB vacci e design strategies include the development of post-
infection vaccines that incorporate antigens presumed to be expressed during 
latency (Andersen, 2007b). The aim of this vaccine strategy is to target 
latently infected individuals that represent a reservoir of M.tb with the potential 
for reactivation and a source of disease transmission. Currently, the vast 
majority of vaccine candidates tested are aimed at preventing primary disease 
and/or reactivation of latent infection through prophylactic vaccines. Although 
these vaccines allow for maintenance of a stable infection, they do not 
achieve sterile eradication of M.tb. Post-infection vaccines may not only 
maintain latent infection and thus prevent reactivation of TB disease but also 
eradicate dormant bacteria and hence induce sterile clearance of M.tb. To 
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date there has been no consistent success in the attempts to use prophylactic 
vaccine candidates as post-infection vaccines (Aagaard et al., 2009). It is 
hypothesized that inducing robust T cell responses to latency associated 
antigens (see below) may enhance immunological control of latent TB. 
Therefore, a rational strategy might be to target latent infection with post-
exposure vaccines expressing latency-, starvation-, or resuscitation-
associated antigens.  
 
The search for novel latency associated antigen(s) has been facilitated by 
expression profiling of M.tb laboratory strains cultured under conditions that 
mycobacteria encounter in situ during latent infection. Latency antigens can 
be defined as those expressed by dormant or slowly replicating M.tb bacilli, 
grown under in vitro conditions that mimic the granuloma. The dormancy 
survival regulon (DosR) is a distinct set of 48 genes that have been shown to 
be upregulated under conditions of hypoxia and nitric oxide stress. Starvation 
antigens expressed by M.tb under in vitro conditions of nutrient starvation are 
known as antigens of the starvation stimulon compromising antigens Rv2656-
2661 (Betts et al., 2002). Resuscitation antigens are expressed during 
reactivation of dormant bacilli, which subsequently resume active metabolism. 
This process is facilitated by so-called resuscitation promoting factors (rpfs) 
that are secreted from slowly replicating bacteria (Downing et al., 2005).  
 
The screening for recognition of antigens expressed by dormant or slowly 
replicating M.tb in latently infected individuals is the first step. Thus far clinical 
studies have focused on antigens of the DosR. T cell recognition of selected 
DosR antigens has been demonstrated in latently infected individuals from a 
non-TB endemic area (Leyten et al., 2006). In addition, immune recognition of 
five DosR antigens, namely, Rv1733, Rv0081, Rv1735c, Rv1737c and 
Rv3131, in latently infected individuals from TB endemic regions of South 
Africa, Uganda and Gambia have also been shown (Black et al., 2009). The 
current study is the first to investigate human recognition of antigens from the 
starvation stimulon. It is important that candidate M.tb antigens from these 
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antigenic groups initially be screened in human populations to assess the 
breadth of immune recognition. In addition, since cell mediated immune 
responses are known to be essential for the control of M.tb, antigens inducing 
a strong TH1 response during natural infection should be chosen as candidate 
antigens for potential inclusion in post-infection vaccines. 
 
1.5 Optimal measurement of vaccine responses 
Efficient and sensitive measurement of T cell responses is absolutely critical 
for the assessment of new vaccines, and for assessment of the human 
immune response to M.tb (Hanekom et al., 2004). At SATVI, we are actively 
involved in assessing novel TB vaccines in clinical trials, and multiple 
immunological studies are conducted to gain insight into the immune 
response to TB infection and disease. It is critical that the appropriate assay is 
employed to address a specific question. The assay system chosen to 
measure vaccine-induced responses, may be guided by the aspect of T cell 
immunity to be measured; for example, longer-term assays may be better for 
measuring central memory T cell responses thought to be critical for long-term 
protection induced by vaccines. The assay system used can also be dictated 
by what is practical in the setting; for example, if incubation of whole blood or 
PBMC isolation early after blood collection is not possible, it may be wiser to 
perform longer-term diluted whole blood or PBMC assays, to minimise a 
potentially significant effect of processing delay on assay outcomes. Blood 
volume restriction in infants, compared to adults, may further dictate assay 
choice (Hanekom et al., 2008). T cell assays that are widely used in vaccine 
trials include 5 to 7 day whole blood or PBMC-based assays of proliferation, 
overnight or 48 hour enzyme-linked immunosorbent spot assays (ELISPOT) 
and 6 to 18 hour-incubation of whole blood or PBMC with specific antigens to 
measure T-cell-specific cytokine expression (Hanekom et al., 2008). 
 
In short-term assays, whole blood or PBMC are typically incubated with 
specific antigens for 6 to 18 hours. Brefeldin-A or monensin is added for the 
last few hours of incubation to capture cytokines intracellularly. Hanekom et 
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al. developed and optimised a whole blood intracellular cytokine detection 
assay (WBA) for assessing T cell responses. This assay is utilized in all our 
vaccine trials and facilitates the harmonization of vaccine assessment in the 
TB field. In the WBA, blood is collected and processed within 2 hours of 
collection, and incubated with antigen for 12 hours. The vaccine-specific 
response measured directly ex vivo, provides a “snapshot” of the host 
immune response and results reflect the in vivo state of circulating T cells 
(Hanekom et al., 2004; Hanekom, 2005). Also, the effector function of specific 
cells is assessed without a prolonged period of cell activation, not allowing 
time for cellular division, resulting in more quantitative outcomes. The WBA is 
a sensitive and reliable way of measuring mycobacteria specific and vaccine-
specific T cell immunity. For short-term assays it is important that whole blood 
is incubated and PBMC isolated and incubated as soon as possible after 
collection, to avoid loss of sensitivity. This appears to be of particular concern 
when protein or whole bacterial or viral antigens need to be processed, and 
may be less important for peptide antigens (Hanekom et al., 2008). 
 
In long-term assays, diluted whole blood or PBMC is incubated with specific 
antigens for 5 to 7 days. Proliferation of T cells in the diluted whole blood 
culture may be measured by thymidine incorporation, or alternatively, by 
detecting BrdU incorporation into nucleic acids. PBMC may be stained with 
the fluorescent dyes CFSE or Oregon Green (OG), prior to incubation, 
allowing detection of proliferation by dilution of the dyes. CFSE and OG bind 
non-specifically to intracellular proteins and each cellular division decreases 
the fluorescence intensity of the cell by half. These assays may also be 
adapted to measure the cytokine-producing potential of the proliferating cells, 
by adding PMA/ionomycin, which causes calcium influx with cytokine 
production, and Brefeldin-A, which blocks export of proteins, including 
cytokines (Hanekom et al., 2008). The capacity for antigen-specific T cells to 
proliferate and clonally expand, which is important in long-lived protective 
immunity, may constitute a different aspect of an ex vivo measurable immune 
response (Rosenberg et al., 1997). Also, the expansion of cells may increase 
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sensitivity, i.e., ability to measure a response not measurable with other 
systems. The monitoring of vaccine-induced T cell proliferative potential may 
be important for determining vaccine take, memory function and long-term 
persistence of vaccine-specific responses. Hence, novel TB vaccine 
candidates should be assessed for their potential to induce durable responses 
in recipients; an outcome that can be optimally measured by a proliferation 
assay adapted for large studies in the field.  
 
1.6. Current studies 
In this thesis, we attempt to address two relevant areas in TB vaccinology. 
Firstly, the screening of human populations for an immune response to novel 
M.tb latency-associated antigens, and the characterisation of this immune 
response. The long-term goal would be inclusion of promising candidates into 
a post-infection vaccine. Secondly, we address the development and 
optimisation of a novel immunological assay for measurement of vaccine-
specific responses. 
 
1.6.1 Study 1 (Chapter 3) 
Objective: To investigate human T cell responses to M.tb latency associated 
antigens in latently infect d and TB diseased patients.  
Specific aims: (i) To determine human antigen recognition of M.tb latency 
associated antigens Rv2659 and Rv2660, by measurement of soluble IFN-γ 
response to the specific antigens, and hence determine the proportion of 
responders to these antigens, and (ii) To determine the cytokine expression 
and proliferative capacity of T cells recognising latency associated antigens in 
LTBI and TB diseased persons. 
 
1.6.2 Study 2 (Chapter 4) 
Objective: To determine whether antigen-specific lymphoproliferation, after 
long-term culture, can be identified through the analysis of Ki67 expression in 
T cells.  
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Specific aims: (i) To determine the kinetics of Ki67 expression in T cells 
following long-term culture with antigen, (ii) To determine how Ki67 as an 
indicator of antigen-specific T cell proliferation compares with standard 
proliferation assays, (iii) To determine how the functional profiles of Ki67 
expressing, proliferating T cells compare with those of proliferating cells 
detected with standard assays, and (iv) To evaluate performance of the Ki67-
based assay for longitudinal assessment of immune responses to vaccination 
in infants.  
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Chapter 2: Assay Optimisation 
The aim of this chapter was to determine which T cell assay system resulted 
in optimal measurement of Rv2660 and Rv2659-specific T cell responses. To 
optimally measure the immune response to the novel latency associated 
antigens Rv2659 and Rv2660 (Chapter 3), both short-term whole blood 
(intracellular cytokine expression) and long-term PBMC and whole blood 
(lymphoproliferation) assays were compared. The outcomes of short-term 
assays, often called “directly ex vivo” assays, reflect the in vivo state of 
circulating T cells. Additionally the effector function of specific cells is 
assessed without a prolonged period of cell activation, not allowing time for 
cellular division. The result may be considered a quantitative reflection of 
immune status in peripheral blood (Hanekom et al., 2008). On the other hand, 
lymphoproliferation assays allow for the expansion of antigen-specific cells, 
enabling the measurement of rare populations that might otherwise be 
undetectable. The capacity of antigen-specific T cells to proliferate and 
produce cytokines may be assessed. Furthermore, it has also been proposed 
that central memory cells may be more optimally measured with 
lymphoproliferation assays (Hanekom et al., 2008). After stringent 
optimisation of these 2 assay systems, the results were compared to 
determine the most sensitive and practical assay to characterise the immune 
response to the latency associated antigens Rv2660 and Rv2659. 
 
2.1. Materials and Methods 
2.1.1 Blood collection 
Blood was collected from healthy adults with a positive QuantiFERON®-TB 
Gold In-Tube (QFT™) test, all of whom had no history of TB disease. Blood 
was collected in sterile tubes containing heparin to avoid blood clotting. The 
blood was collected using a UCT Research Ethics Committee-approved 
protocol, which included written informed consent obtained from all 
participants. 
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2.1.2 Short-term whole blood assay 
We first conducted a short-term whole blood assay to determine direct ex vivo 
responses to Rv2660 and Rv2659. Whole blood was collected in heparinized 
syringes and processed within 2 hours of collection. Briefly, 500µL undiluted 
whole blood was incubated for 12 hours at 37°C with Rv2660 peptide pool 
(20mers, overlapping by 10 amino acids, final concentrations of 1, 3 and 
10µg/mL/peptide), or Rv2659 peptide pool (20mers, overlapping by 10, final 
concentration 1, 3 and 10µg/mL/peptide) (provided by Staten Serum Institute) 
or viable BCG (reconstituted from the vaccine vial, Danish strain, Staten 
Serum Institute, 1.2 x 106 CFU/mL) and the co-stimulatory antibodies anti-
CD28 and anti-CD49d (BD Biosciences, 0.5µg/mL each). These antibodies 
are known to enhance the frequency of antigen-specific cytokine expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Flow diagram depicting the whole blood intracellular cytokine assay 
(Hanekom et al.).  
 
Five-hundred microlitres of blood incubated with Staphylococcal enterotoxin B 
(SEB, Sigma-Aldrich, 10µg/mL) and 500µL incubated with the co-stimulatory 
antibodies alone (unstimulated) served as positive and negative controls, 
respectively. After 7 hours, 100µL supernatant was collected and stored at -
80°C. Brefeldin A (Sigma, 10µg/mL) was added for the last 5 hours of 
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incubation. Following EDTA harvest, red blood cells were lysed and white 
cells fixed with BD FACS Lysing Solution (BD Biosciences), and the cells 
cryopreserved. Please refer to figure 2.1 for a flow diagram of the method. 
 
2.1.3 Six-day whole blood BrdU incorporation assay 
Next we determined whether the expansion of Rv2660 and Rv2659-specific T 
cells would allow greater sensitivity in the measurement of the immune 
response to these antigens. Whole blood (125μL diluted 1:10 in warm RPMI 
1640) was incubated with Rv2660 peptide pool (as in section 2.1.2), Rv2659 
peptide pool (as in 2.1.2) or 1 x 105cfu/mL viable Danish BCG, in duplicate 
wells in 96 well culture plates for 6 days at 37°C with 5% CO2. On day 6 (day 
3 for PHA), 10µmol/L BrdU (Sigma-Aldrich) was added for the last 5 hours of 
culture. To induce cytokine expression and capture the cytokines 
intracellularly, 10ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma-
Aldrich), 1.5µg/mL ionomycin (Sigma-Aldrich) and 1.5µg/mL Brefeldin A 
(Sigma-Aldrich) were also added during the last 5 hours of culture. Control 
antigens included 1µg/mL phytohaemagglutinin (PHA; positive control, Sigma-
Aldrich), medium only (Uns, negative control) or, for intracellular cytokine 
assays, medium with PMA and ionomycin (Uns-PI). On day 6, 100µL 
supernatant was collected and stored at -80°C. Cells were harvested with 
2mM EDTA (Sigma-Aldrich) and red blood cells lysed and fixed using BD 
FACS Lysing Solution (BD Biosciences), according to the manufacturerʼs 
instructions and cryopreserved until analysis. 
 
The assay was further optimised by: 
1) Staining of white blood cells with a viability dye, LIVE/DEAD Fixable 
Violet Dead Cell Stain Kit (ViViD, Invitrogen). Prior to staining with the 
viablity dye, red blood cells were lysed using an ammonium chloride-
lysing solution which contained no fixative. This was followed by fixing 
and cryopreservation of cells.  
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2.1.4 Flow cytometric analysis of processed whole blood 
Cryopreserved cells were later thawed and washed in phosphate buffered 
saline (PBS, BioWhittaker), and permeabilised using Perm/Wash Solution (BD 
Biosciences). The following monoclonal antibodies were used for phenotypic 
and/or intracellular cytokine staining: CD3-QDot 605 (UCHT1), CD8-
PerCPCy5.5 (SK1), IFN-γ-Alexa Fluor 700 (B27), TNF-α-PECy7 (MAb11), IL-
2-APC (MQ1-17H12), anti-BrdU-FITC (B44). ViViD, which fluoresces in the 
Pac-Blue channel was compensated using PacBlue (UCHT1) antibody. All 
antibodies were from BD Biosciences except for CD3-QDot 605, which was 
from Invitrogen. Samples were acquired on a BD LSRII flow cytometer (BD 
Biosciences, San Jose, CA), configured with 3 lasers and 10 detectors, using 
the FACS Diva 6.1 software. Compensation settings were defined using anti-
mouse kappa beads (BD Biosciences) that were stained with the respective 
fluorochrome–conjugated antibodies. 
 
2.1.5 Six-Day PBMC Oregon Green assay 
Next, a 6-day PBMC assay was performed to determine whether whole blood 
and PBMC-based lymphoproliferation assays both result in expansion of 
Rv2660 and Rv2659-specific T cells. PBMC were isolated by density gradient 
centrifugation and cryopreserved in 10% DMSO (Sigma-Aldrich) in heat-
inactivated fetal calf serum (Adcock Ingram). PBMC were thawed in 12.5% 
human AB serum/ RPMI containing 2.5µg/mL DNase (Sigma-Aldrich) and 
stained with 10µg/mL of Oregon Green (OG) (Molecular Probes, Invitrogen). 
The PBMC were resuspended in 12.5% AB serum in RPMI, and 200,000 cells 
in 200µL medium were rested overnight at 37oC, 5% CO2 in a 96 well plate. 
Duplicate wells containing cells were either stimulated with BCG at an MOI of 
0.01, Rv2660 peptide pool (as in 2.1.2), Rv2659 peptide pool (as in 2.1.2), or 
SEB (0.05µg/mL, positive control) or no antigen (negative control), for 6 days 
at 37oC with 5% CO2. All antigens were obtained from the Staten Serum 
Institut, Denmark. After incubation, plasma was collected and stored at -80oC 
until further use. PBMC were then incubated with PMA (50ng/mL) and 
ionomycin (250ng/mL) to induce cytokine production, and Brefeldin A 
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(10µg/mL) was added for a further 5 hours. PBMC were harvested, stained for 
viability with ViViD, fixed with FACS Lysing Solution, and cryopreserved until 
later analysis.  
 
2.1.6 Flow cytometric analysis of processed PBMC 
Fixed, cryopreserved PBMC were thawed, washed with PBS and 
permeablised with Perm/Wash Solution for 10 minutes. PBMC were stained 
with the following antibodies: anti-CD3 Qdot605 (clone UCHT1) anti-CD8 
Cy5.5PerCP (SK-1) and anti-IFN-γ AlexaFluor700 (B27), (all from BD 
Biosciences) for 1 hour at 4oC. After washing, cells were acquired on a LSRII 
flow cytometer (BD Biosciences), as in 2.1.4 Oregon Green and ViViD were 
compensated with FITC and PacBlue respectively. Data was analyzed using 
Flowjo 8.8.4 (Treestar). See figure 2.2 for illustration of method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Flow diagram depicting the PBMC–based 6-day Oregon Green intracellular 
cytokine assay. (Diagram obtained from Alana Keyser, SATVI 2010)  
 
2.1.7 IFN-γ measurement in supernatants  
To determine whether Rv2660 and Rv2659 were recognised by LTBI 
individuals, soluble IFN-γ responses to the antigens were measured as 
indication of an antigen recognition. Briefly, 96-well plates were coated with 
2µg/mL of anti-IFN-γ mAb (Pharmingen) for 2 hours at 37oC, and blocked with 
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1% BSA (Roche diagnostics) in PBS for 1 hour at 37oC. IFN-γ standard (15.6-
2000pg/mL) (Pharmingen) and supernatants derived from the whole blood 
assay were added to the pre-coated plates, and incubated at 4oC overnight. 
After washing, appropriate wells were incubated with 1µg/mL biotin-labeled 
mouse anti-human IFN-γ mAb (Pharmingen) for 45 mins at room temperature 
(RT), followed by streptavidin peroxidase for 30 mins. OPD Fast (Sigma) was 
utilized as substrate, and the reaction stopped with 2M H2SO4 after 40 mins 
development. Plates were read at 405 nm on a Versemax ELISA plate reader 
using Softmax Pro software Version 4.7.1. The limit of detection of the IFN-γ 
ELISA was 15.6pg/mL. 
 
2.1.8 IL-2 measurement in supernatants  
As for IFN-γ, soluble IL-2 measurement was also performed as an antigen 
recognition screen. The IL-2 ELISA was carried out similarly to the IFN-γ 
ELISA with the following exception: Plates were coated with 4µg/mL of anti-IL-
2 mAb (Pharmingen). The IL-2 standard (15.6-1000pg/mL) (Pharmingen) and 
supernatants were incubated at 4oC overnight. After washing, appropriate 
wells were incubated with 1µg/mL biotin-labelled mouse anti-human IL-2 mAb 
(Pharmingen). The limit of detection of the IL-2 ELISA was 15.6pg/mL. 
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2.2. Results 
2.2.1 Detection of soluble IL-2 and IFN-γ depends on the duration of the 
assay  
To assess whether Rv2660 and Rv2659-induced IL-2 and IFN-γ can be 
detected by both long and short-term PBMC and whole blood assays, 
supernatants from both the short-term and long-term assays were collected 
and cytokine levels determined by ELISA.  
 
Supernatant from the direct ex vivo assay whole blood assay revealed that 
IFN-γ was only detected after incubation with the highest concentration 
(10µg/mL/peptide) of Rv2660 and Rv2659 (Figure 2.3A); however, IL-2 was 
detected at all 3 concentrations of the antigens, albeit at low levels (Figure 
2.3B). Conversely, analysis of a long-term whole blood assay revealed that 
IFN-γ but not IL-2 (Figure 2.3C and D) was detected in the supernatants at all 
concentrations of antigens. IFN-γ was also detectable in supernatants from 
PBMCs incubated with Rv2660 and Rv2659 at all 3 concentrations for 6 days 
(Figure 2.3E), which verified that results from whole blood and PBMCs could 
assess similar IFN-γ levels after stimulation with viable BCG and SEB after 6 
days of culture. 
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Figure 2.3. Detection of soluble IL-2 and IFN-γ  in short- and long-term assays, by 
ELISA. Detection of IFN-γ (A) and IL-2 (B) from supernatants of direct ex vivo whole blood 
assay. Detection of IFN-γ (C) and IL-2 (D) from supernatants of a 6-day whole blood assay. 
Detection of IFN-γ (E) from supernatants of Oregon Green PBMC assay. (n=3) for all assays 
(*undetectable). 
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2.2.2 Rv2660 and Rv2659-specific T cell responses are barely detectable 
using the direct ex vivo intracellular cytokine assay 
To be able to more comprehensively characterise the antigen-specific T cell 
response to Rv2660 and Rv2659, multiparameter flow cytometry was utilized. 
Whole blood incubated for 12 hours with Rv2660 and Rv2659 resulted in 
minimal T cell responses, which were barely above background levels (Uns) 
(Figure 2.4). We concluded that the latency antigen specific response 
detected by the short-term intracellular cytokine assay was too small to allow 
reliable measurement and characterisation of the T cell response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Gating strategy and detection of latency antigen specific CD4+ T cells 
producing IFN-γ  and/or IL-2 from the direct ex vivo whole blood assay. (A) Doublet cells 
were excluded by gating on forward scatter-height (FSC-H) against forward scatter-area 
(FSC-A). CD3+ lymphocytes were selected by gating on CD3+ against side scatter area (SSC-
A). CD3+ T cells were further differentiated into CD4+ and CD8+ T cell subsets by staining for 
CD8+ and CD4+ T cells, and then cytokine expression patterns were analyzed. (B) 
Representative dot plots of cytokine co-expression patterns in unstimulated or antigen-
specific CD4+ T cells. Results are representative of two healthy LTBI adults. 
 
2.2.3 Cell viability is compromised after long-term incubation of whole blood 
with antigen 
Cell death occurs during longer-term (up to 7 days) incubation of whole blood 
or PBMC, hence we assessed exclusion of dead cells with viability dye ViViD. 
This dye works by binding to amines that are on the cell membrane. 
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Apoptosis results exposure of intracellular amines on the cell membrane; 
therefore, dead cells (ViViDhigh) will fluoresce at a higher intensity for ViViD 
than live cells (ViViDlow). Figure 2.5 shows that after long-term stimulation of 
whole blood with a potent antigen such as viable BCG, cell viability is 
compromised - approximately 20% cell death was detected. These dead cells 
could be excluded by gating on CD3+ and ViViDlow cells (Figure 2.5). In the 
absence of a viability dye, total CD3+ cells will include both viable and non-
viable T cells (Figure 2.5A). It is evident from panel A that dead cells fluoresce 
in the FITC channel (BrdU), by binding non-specifically to antibodies This is 
observed when comparing the frequency of proliferating cells in the total CD3+ 
population (Figure 2.5B, no ViViD) with the live CD3+ population (Figure 2.5C, 
ViViD included). The incorporation of ViViD into the analysis strategy results 
in clear delineation of positive and negative populations, and enables more 
reliable results to be generated (Figure 2.5C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Incorporation of ViViD into a 6-day lymphoproliferation whole blood assay. 
Dead cells incorporate the viability dye, ViviD, and viable CD3+ T cells are selected by gating 
on ViViDlow cells. CD3+ T cells were further differentiated into proliferating (BrdU+) CD4+ and 
CD8+ T cell subsets by staining for CD8+ (CD3+CD8- = CD4+ T cells). Optimisation 
experiments showed that using only a CD8 antibody resulted in clear delineation of CD8+ and 
C8- (CD4+) populations. Results are representative of two healthy LTBI adults 
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2.2.4 Expansion of Rv2660 and Rv2659-specific T cells by 6-day whole blood 
lymphoproliferation assay 
Since the short-term WBA resulted in a barely detectable frequency of 
Rv2659- and Rv2660-specific T cells, a lymphoproliferation assay was 
assessed. This would allow expansion of rare antigen-specific T cell 
populations. Rv2660- and Rv2659-specific T cells were expanded for 6 days 
in culture with their respective peptide pools, and were detected by the 
incorporation of BrdU. The potential of specific (i.e., proliferating) CD4+ to 
produce IFN-γ and TNF-α was subsequently determined from the BrdU+ T 
cells. We showed that after polyclonal activation proliferating Rv2660-specific 
CD4+ T cells and associated cytokine production were detectable using this 
assay (Figure 2.6). Background levels were very low, and stimulation with 
viable BCG or PHA (positive control) resulted in significant T cell proliferation 
and cytokine expression. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Expansion of Rv2660- and Rv2659-specific T cells in a 6-day BrdU whole 
blood lymphoproliferation assay. Frequency of CD4+ BrdU+ proliferating cells expressing 
IFN-γ and/or TNF-α upon stimulation with the indicated conditions. Proliferating CD4+ T cells 
are selected by gating on BrdU against SSC-A, and then cytokine expression patterns were 
then determined after polyclonal activation with (PMA/Ionomycin) in proliferating T cells. The 
numbers within the gated areas indicate the frequency of BrdU+ (A) (proliferating) or the 
frequency of CD4+ T cells producing cytokines (B). Results are representative of two healthy 
LTBI adults.  
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2.2.5 Expansion of Rv2660- and Rv2659-specific T cells by PBMC-based 6-
day Oregon Green assay 
Since only PBMC were available for analysis from one group to be studied, 
TB diseased patients, (Chapter 3), a PBMC-based assay was optimised to 
investigate immune responses to the novel antigens. Specifically, a PBMC-
based Oregon Green (OG) 6-day assay was assessed to ascertain whether 
this assay would be practical and reliable for detecting Rv2660- and Rv2659-
specific T cell responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Expansion of Rv2660- and Rv2659-specific T cells in a PBMC-based 6-day 
Oregon Green assay. Frequency of CD4+ proliferating cells expressing IFN-γ. PBMC were 
isolated, labelled with OG, and either left unstimulated or stimulated with the antigens 
indicated. Doublet cells were excluded by gating on forward scatter-height (FSC-H) against 
forward scatter-area (FSC-A), and viable T cells were then selected by gating on CD3+ 
against ViViD. CD3+ T cells were further differentiated into CD4+ and CD8+ T cell subsets by 
staining for CD8+ (CD3+CD8- = CD4+ T cells, CD3+CD8+ = CD8+ T cells). Proliferating (OGlow) 
CD4 T cells were then selected by gating OG against IFN-γ after polyclonal activation with 
(PMA/Ionomycin). Results are representative of three healthy LTBI adults. 
 
Similarly to the BrdU whole blood assay, the PBMC OG assay resulted in 
expansion of Rv2660- and Rv2659-specific T cells, and enabled reliable 
detection of these populations (Figure 2.7). Therefore, the OG 
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lymphoproliferation assay was selected to characterise Rv2660- and Rv2659-
specific T cell responses for the study (Chapter 3). 
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2.3. Discussion 
It is critical that the appropriate assay is employed to address a specific 
question, and that the assay is carefully optimised to ensure the most 
sensitive and reliable outcomes. To this end, several assays were compared 
to determine which system allowed optimal measurement of Rv2660- and 
Rv2659-specific T cell responses. A direct ex vivo whole blood assay was 
initially assessed, however incubation with Rv2660 and Rv2659 resulted in a 
negligible antigen-specific T cell response. Soluble IL-2 and to a lesser extent, 
IFN-γ levels, were measureable with this short-term assay, however the low 
levels of soluble and intracellular cytokines measured, led to the exclusion of 
this assay. 
 
Since cellular responses could not be reliably m asured with a short-term 
assay, we assessed 6-day lymphoproliferation assays, which might facilitate 
the expansion of rare T cell populations. The BrdU whole blood assay, a 
routinely used lymphoproliferation assay (Dolbeare et al., 1983; Houck and 
Loken, 1985; Rosato et al., 2001), yielded reliable results and enabled the T 
cell-associated cytokine profiles to be dissected. Although cell death does 
occur after long-term incubation of whole blood with antigens, we 
demonstrated that inclusion of a viability dye in the analysis strategy resulted 
in a more reliable outcome. We conclude that the whole blood 
lymphoproliferation assay did result in the expansion of Rv2660 and Rv2659-
specific T cells. The inclusion of a viability dye into long-term whole blood 
lymphoproliferation assays is vital for exclusion of dead cells. Dead cells bind 
non-specifically to antibodies making a clear delineation of positive and 
negative cell populations difficult.  
 
Importantly, compared with the short-term assay, the long-term assay enabled 
the detection of soluble IFN-γ by ELISA, a classical screening tool for antigen 
recognition prior to further T cell characterisation. Unlike in the short-term 
assay, IL-2 was not detectable with the long-term assay, which may be due to 
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the consumption of IL-2 by antigen-specific proliferating T cells (Cheever et 
al., 1984). Since soluble IFN-γ measurement was proven to be the more 
reliable indication of antigen recognition, this outcome was chosen for the 
study. 
 
During the optimisation period, we acquired cryopreserved PBMC samples 
from TB patients, which necessitated the optimisation of a PBMC–based long-
term proliferation assay. Preliminary studies with a 6-day OG 
lymphoproliferation assay revealed that Rv2660- and Rv2659-specific T cell 
responses were measureable and consistently reliable with the small sample 
sizes that were use for optimisation. We finally selected the 6-day PBMC-
based OG lymphoproliferation assay, which provides 2 independent readouts: 
(i) measurement of soluble IFN-γ for screening of T cell immune 
responsiveness to Rv2660 and Rv2659 (ii) flow cytometry characterisation of 
the Rv2660- and Rv2659-specific T cell responses. 
 
2.4 Contributions 
Lerisa Govender designed the experiments, conducted the laboratory and 
data analysis, and wrote this chapter under supervision of Prof. W.A. 
Hanekom, Dr. B. Abel, Ms Jane Hughes and other members of SATVI 
laboratory.  
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3.1. Abstract 
One third of the worldʼs population is infected with Mycobacterium tuberculosis 
(M.tb). Only 10% of these persons will develop TB disease. A vaccine that 
would prevent progression to TB disease will have a dramatic impact on the 
worldwide TB burden. We propose that antigens of M.tb that are preferentially 
expressed during latent infection will be excellent candidates for post-
exposure vaccination. We therefore assessed human T cell recognition of two 
antigens of M.tb, Rv2660 and Rv2659, expression of which have been shown 
to be associated with latency in vitro, and which show promise as post-
infection vaccine candidates in animal models. In a pilot study IFN-γ 
responses to Rv2660 and Rv2659 were measured in the whole blood of 21 
persons with latent tuberculosis infection (LTBI). Thereafter, PBMC from 
persons with LTBI and with tuberculosis (TB) disease were incubated with 
Rv2660 and Rv2659 for six days. Soluble IFN-γ levels in supernatants were 
quantified by ELISA, and CD4+ and CD8+ T cell proliferation, and cytokine 
producing capacity of proliferating cells, determined by flow cytometry. Rv2660 
and Rv2659 induced IFN-γ production in a greater proportion of persons with 
LTBI, compared with patients with TB disease. Persons with LTBI also had 
increased viable CD3+ lymphocytes and greater specific CD4+ T cell 
proliferation and cytokine expression capacity, compared with patients with 
TB disease.  
Persons with LTBI preferentially recognize Rv2659 and Rv2660, compared 
with patients with TB disease. These results suggest promise of these 
antigens for incorporation into post-exposure TB vaccines. 
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3.2. Introduction 
The success of M.tb as a human pathogen may be ascribed to its ability to 
persist for long periods in asymptomatic people, a state known as latency 
(Andersen, 2007b). Healthy latently infected individuals have approximately 
10% lifetime risk of developing active TB disease (Flynn and Chan, 2001). 
This risk increases to approximately 10% per year in HIV-infected persons not 
on antiretroviral therapy (Corbett et al., 2003). Approximately one third of the 
worldʼs population is infected with M.tb, 9 million develop TB disease and 1.8 
million die annually (Baumann et al., 2006; WHO Report., 2009). To control 
this pandemic, an effective vaccine is urgently needed; however, this requires 
extensive insight into the mechanisms underlying protective immunity against 
M.tb. 
 
The low bacterial burden associated with a latent infection has proven to be a 
major obstacle in characterizing the mechanisms by which M.tb persists and 
reactivates in the host (Flynn and Chan, 2001). In latent granulomatous 
lesions, M.tb is successfully contained and has to adapt to a hypoxic and 
nutritionally compromised environment (Sherman et al., 2001). It has recently 
been hypothesized that this immune pressure drives M.tb into a different 
metabolic state, compared with actively replicating organisms in lesions that 
characterize early M.tb infection or active disease (Andersen, 2007b). This is 
supported by findings from in vitro studies which mimic the granuloma 
environment, where M.tb was shown to upregulate sets of genes that are 
distinct from those upregulated in actively replicating organisms; e.g., in 
nutrient deficient medium, a particular set of genes that were termed the 
“starvation stimulon” were upregulated (Betts et al., 2002). We focused on 2 
proteins of the starvation stimulon, Rv2660 and Rv2659, and hypothesized 
that these antigens will be preferentially recognised by persons with latent 
M.tb infection (LTBI),, compared with persons with TB disease. Rv2660 and 
Rv2659 belong to the RD11 region encoded in M.tb (Gordon et al., 2001), 
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however the function of these proteins has not been determined (Betts et al., 
2002).  
 
The rationale for these studies is that the antigens might in the future be 
incorporated into novel post-exposure TB vaccines, which could protect 
infected individuals from developing TB disease (Andersen, 2007b). 
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3.3. Materials and Methods 
3.3.1 Study participants 
Participants were recruited from the Western Cape region of South Africa. 
Persons with latent TB infection (LTBI) were included if they had a positive 
QuantiFERON®-TB Gold In-Tube (QFT™) test, or a positive ELISPOT test for 
ESAT-6/CFP-10 (>17 spots/106 PBMC after background subtraction), or a 
positive Mantoux skin test (induration >10mm), for greater than 1 year at the 
time of recruitment. Any clinical signs or symptoms suggestive of TB disease, 
a history of TB treatment, HIV infection, any other acute or chronic medical 
conditions, receipt of immunosuppressive medication, or a haemoglobin level 
<9g/dL resulted in exclusion. Patients with TB disease were included if they 
had 2 positive sputum smears and/or a positive culture, with clinical features 
consistent with TB disease. Patients with extra-pulmonary TB disease were 
excluded, as were patients with exclusion criteria mentioned for LTBI above. 
Informed consent was obtained from all participants prior to study 
participation. The study was approved by the research ethics committees of 
the University of Cape Town and the University of Stellenbosch.  
 
3.3.2 Whole blood incubation 
Whole blood was collected in heparinised syringes. Blood was diluted in RPMI-
1640 medium (Sigma) containing 1% L-glutamine (Sigma, final dilution 1:10), 
and incubated with an ESAT-6 peptide pool (17mers, overlapping by 10, final 
concentration 1µg/mL/peptide), CFP-10 peptide pool (17mers, overlapping by 
10, final concentration 1µg/mL/peptide), TB10.4 protein (10µg/mL), Rv2660 
peptide pool (20mers, overlapping by 10, final concentration 1µg/mL/peptide), 
or Rv2659 peptide pool (20mers, overlapping by 10, final concentration 
1µg/mL/peptide), in 200µL volumes in 96-well U-bottom plates (Nunc, Cat No 
163320), for 6 days at 37oC in 5% CO2. All antigens were obtained from the 
Statens Serum Institut, Denmark. Blood incubated without antigen and blood 
incubated with phytohaemagglutinin (PHA, 5µg/mL) were used as negative and 
positive controls, respectively. After incubation, 150µL culture supernatant was 
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removed and stored at -80oC until further analysis.  
 
3.3.3 Six-Day PBMC Oregon Green assay 
Performed as described in chapter 2 (section 2.1.5) with the following 
inclusions: Duplicate wells (i.e. 400,000 PBMC per condition) containing cells 
were either stimulated with BCG (1331 Danish BCG) at an MOI of 0.01, PPD 
(0.5µg/mL), an ESAT-6/CFP10 peptide pool (2µg/mL/peptide); a combination 
of separate ESAT-6 and CFP10 peptide pools was used due to a limited 
number of PBMCs from TB patients, TB10.4 peptide pool (15mers, 
overlapping by 10, final concentration 1µg/mL/peptide), Rv2660 peptide pool 
(final concentration 1µg/mL/peptide), Rv2659 peptide pool (final concentration 
1µg/mL/peptide), or SEB (0.05µg/mL, positive control, Sigma-Aldrich) or no 
antigen (negative control), for 6 days at 37oC with 5% CO2.  
 
3.3.4 Flow cytometric analysis of processed PBMC 
Performed as described in chapter 2 (section 2.1.6) with the following 
changes: PBMC were washed with PBS and stained with the following 
antibodies: anti-CD3 Qdot605 (clone UCHT1) anti-CD8 PerCPCy5.5 (SK-1), 
anti-IFN-γ AlexaFluor700 (B27), anti-IL2 APC (MQ1-17H12) and anti-TNF-a 
Cy7.PE (MAb11) (all from BD Biosciences) for 1 hour at 4oC. After washing, 
cells were acquired on a LSRII flow cytometer (BD Biosciences), configured 
with 3 lasers and 10 detectors, using the FACS Diva 6.1 software. 
Compensation settings were defined using anti-mouse kappa Comp Beads 
(BD Biosciences) stained with each fluorochrome–conjugated antibody. 
Because the cellular dyes Oregon Green and ViViD do not bind Comp Beads, 
compensation of these dyes was done using FITC and Pacific Blue 
conjugated antibody-bound Comp Beads, respectively. Data was analyzed 
using Flowjo 8.8.4 (Treestar). Frequencies of proliferating and cytokine-
expressing CD4 or CD8 T cells were determined after exclusion of dead cells 
(ViViDhigh events). Since only a CD8 antibody was used, CD4+ T cell 
expression was based on the absence of CD8 expression It is important to 
note that when detecting CD4+ T cells based on the absence of CD8 
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expression, that BCG stimulation of PBMC or whole blood it is possible that 
responding gamma/delta (γ/δ) T cells can also be identified in the CD8- gate. If 
γ/ δ T cells are to be specifically excluded from analysis an additional anti-γ/δ 
T cell stain has to be incorporated. Boolean gating was applied to generate 
combinations of cytokine expressing CD4+ and CD8+ T cell subsets. 
 
3.3.5 IFN-γ measurement in supernatants 
Performed as described in chapter 2 (section 2.1.7). 
 
3.3.6 Data analysis 
For soluble IFN-γ analysis, antigen-specific cytokine levels were determined 
by subtracting levels from unstimulated conditions. A positive IFN-γ response 
was defined as 31.2pg/mL (twice the limit of detection of 15.6pg/mL), after 
background subtraction. 
 
For the flow cytometric assay, proliferation and cytokine expression levels 
from the unstimulated condition (restimulated with PMA and Ionomycin) were 
subtracted from levels obtained after antigen-specific stimulation. Individuals 
were excluded from analysis for samples with <100 viable CD3+ T cells, or if 
the positive control yielded a negative result. Statistical analyses were 
calculated using GraphPad Prism v 5.0. The Mann-Whitney U test was used 
to assess differences between the two groups. The Fisherʼs exact test was 
used to assess differences between proportions of responders. P-values 
<0.05 were considered to be significant. 
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3.4. Results 
3.4.1 Participant Characteristics 
We examined immune recognition of Rv2660 and RV2659, measured by IFN-
γ expression in whole blood in a pilot study on 21 adults with LTBI. The 
median age was 32 years (interquartile range: 28-40); 90% were female. All 
participants had been vaccinated with BCG at birth, and all were from a mixed 
ethnic background. Following the pilot study, PBMC proliferation and cytokine 
production were studied in 25 additional persons with LTBI, as well as 25 
patients with TB disease. The median ages of the LTBI and TB diseased 
groups were 19 years (18.5-31.5) and 31 years (23.5-42), respectively 
(p=0.003); 64% of individuals with LTBI were female, compared with 24% in 
the TB group (p=0.044). Due to the difference in age and gender we 
compared the outcomes with respect to these co-variates. Only polyfunctional 
CD4+ T cells, expressing IFN-γ, TNF-α and IL-2 were different in males and 
females. Participants excluded from analysis, with criteria for exclusion, are 
shown in Supplementary Figure 1. Twenty-eight % of TB patients were 
excluded due either culture contamination or <100 viable CD3+ T cells; 8% of 
LTBI participants were excluded due to a negative SEB result.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 52 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Participant exclusion during the study. Flow diagram indicating the number of 
individuals excluded from the study and criteria for exclusion.  
 
3.4.2 Rv2660 and Rv2659 are recognized by T cells of persons with 
established latency 
To assess whether Rv2660 and Rv2659 are recognised during established 
human latent M.tb infection, diluted whole blood was incubated with the 
antigens for 6 days, and IFN-γ measured in the supernatant. Rv2660 and 
Rv2659 induced detectable IFN-γ production in a high proportion of persons 
with LTBI (Figure 3.2). The immunodominant control antigen, TB10.4, present 
in both BCG and in M.tb, and the M.tb–specific antigens ESAT-6 and CFP-10, 
were recognized in substantially greater proportions of individuals than the 
two latency associated antigens (Figure 3.2). The positive control, SEB 
induced a response in all individuals (data not shown). 
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Figure 3.2. Recognition of novel M.tb antigens Rv2660 and Rv2659 in persons with 
LTBI. Whole blood from persons with LTBI was incubated for 6 days with mycobacterial 
antigens and IFN-γ levels in supernatants measured by ELISA. The proportion of persons with 
a positive response, defined as an IFN-γ level above 31.2pg/mL, following subtraction of the 
IFN-γ level from the unstimulated control, is shown. n = 21 
 
To compare immune recognition of Rv2660 and Rv2659 during established 
latent infection and TB disease, we incubated PBMC with these antigens for 6 
days. The optimum concentrations of Rv2660 and Rv2659 peptide pools were 
assessed for inducing proliferation of CD4+ T cells. Two antigen peptide pool 
concentrations of 1µg/mL/peptide and 10µg/mL/peptide were compared. The 
peptide pool concentration of 1µg/mL was selected for both antigens because 
1µg/mL induced higher frequencies of proliferating CD4+ T cells in both 
cohorts (Figure 3.3A and B), with the exception of Rv2660 in the TB diseased 
group (Figure 3.3A).  
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Figure 3.3. Comparison of Rv2660 and Rv2659 peptide pool concentrations. 
Comparison of Rv2660 (A) and Rv2659 (B) antigen concentrations in LTBI and TB diseased 
individuals. PBMC were stimulated with either 10µg/mL or 1µg/mL of (A) Rv2660 and (B) 
Rv2659, and the level of proliferation assessed by Oregon Green expression. The Wilcoxon 
signed rank test was used to calculate p-values of differences between the 2 groups. LTBI n = 
23, TB n = 18 
 
This was followed by measurement of IFN-γ in supernatants from PBMC of 
LTBI persons and TB diseased patients incubated with Rv2660 and Rv2659 
for 6 days. A greater proportion of persons with LTBI recognised Rv2660 and 
Rv2659, compared with TB diseased patients (Figure 3.4A). A similar 
proportion of persons in the 2 study groups responded to BCG; however, 
more persons with LTBI responded to ESAT-6/CFP-10, compared with TB 
diseased patients. Further, median levels of IFN-γ in response to all antigens 
were higher in the LTBI group, compared with the TB diseased group (Figure 
3.4B).  
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Figure 3.4. Recognition of novel TB antigens in persons with LTBI and with TB 
disease. (A) PBMC derived from persons with LTBI or TB disease were incubated with the 
indicated antigens for 6 days, and IFN-γ levels measured in supernatants by ELISA. 
Proportion of persons with a detectable response, as an IFN-γ level above 31.2pg/mL, 
following subtraction of the IFN-γ level from the unstimulated control, is shown. (B) IFN-γ 
response (pg/ml) to the antigens indicated. The medians are represented by the black 
horizontal bars. A positive response was defined as an IFN-γ level above 15.6pg/mL after 
background subtraction. The Mann-Whitney U test was used to assess differences between 
the 2 groups. LTBI n = 23, TB n = 18 
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3.4.3 Decreased viability of CD3+ T cells during TB disease  
We hypothesized that lower Rv2660 and Rv2659 recognition during TB 
disease is due to lower survival capacity of T cells derived from TB diseased 
patients compared with LTBI persons. After 6 days of incubation of PBMC in 
conditions as aforementioned, cell viability was assessed with flow cytometry 
following staining with ViViD (Figure 3.5A). The LTBI group had significantly 
higher frequencies of viable CD3+ T cells (96.60%) compared to TB patients 
(65.95%), for all conditions tested (Figure 3.5B). The median number of viable 
CD3+ T cells was 15,771 (IQR, 4,912-99,654). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Comparison of CD3+ T cell Viability. Comparison of viable CD3+ T cells in 
PBMC of LTBI and TB individuals stimulated with BCG and M.tb-specific antigens for 6 days. 
(A) Viable T cells were selected by gating on CD3+ T cells against ViViD. (B) Frequency of 
viable CD3+ T cells detected by staining with ViViD. Viable cells were selected by gating on 
CD3+ T cells that stained ViViDlow. The medians are represented by the black horizontal bar. 
The Mann-Whitney U test was used to assess differences between the 2 groups. LTBI n = 23, 
TB n = 18 
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3.4.4 Increased frequency of proliferating Rv2660- and Rv2659-specific CD4+ 
T cells during established latency 
We further characterized viable CD4+ T cell responses to Rv2660 and Rv2659 
during established latent infection and TB disease by assessing viable 
antigen-specific proliferation with a dye dilution assay, and the cytokine 
producing capacity of proliferating cells (Figure 3.6A-B and C, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Gating strategy to analyze the cytokine expression profiles of proliferating 
CD4+ and CD8+ T cells. PBMC were stained with Oregon Green and stimulated with 
mycobacterial antigens, SEB, or were left unstimulated for 6 days, and analyzed by flow 
cytometry. Doublet cells were excluded by gating on forward scatter-height (FSC-H) against 
forward scatter-area (FSC-A) (not shown), and viable T cells were then selected by gating on 
CD3+ against ViViD (Figure 3.5A). (A) CD3+ T cells were further differentiated into CD8- and 
CD8+ T cell subsets (CD3+CD8- = CD4+ T cells, CD3+CD8+ = CD8+ T cells). (B) Proliferating 
(OGlow) CD4+ (indicated by arrow) and CD8+ T cell subsets were selected by gating on OGlow 
T cells. Cytokine expression patterns were then analyzed in proliferating T cells. (C) 
Representative dot plots of cytokine co-expression patterns in unstimulated or antigen-
specific proliferating CD4+ T cells. LTBI n = 23, TB n = 18. 
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Frequencies of proliferating antigen-specific CD4+ T cells were higher in LTBI, 
compared with TB disease, for all antigens tested but the difference was 
clearly more pronounced for BCG and ESAT6/CFP10 (Figures 3.7A-D, left 
panels). The positive control, SEB induced a response in all individuals (data 
not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Comparison of CD4+ T cell proliferation and intracellular cytokine 
expression in individuals with LTBI and TB disease. CD4+ T cell antigen-specific 
proliferation upon incubation with Rv2660 (A), Rv2659 (B), BCG (C), and ESAT-6/ CFP-10 
(D), detected by gating on Oregon Greenlow CD4+ T cells. Frequencies of CD4+ T cell cytokine 
expression profiles; IFN-γ+TNF-α+IL2+, total IFN-γ+, total TNF-α+ and total IL-2+, of proliferating 
cells following incubation of PBMC with antigens (A-D, right panels), detected by intracellular 
cytokine staining. The medians are represented by the black horizontal bars. The Mann-
Whitney U test was used to assess differences between the 2 groups. LTBI n = 23, TB n = 18 
 
The cytokine expression profile of proliferating CD4+ T cells was assessed by 
adding PMA and ionomycin, for the last 5 hours of incubation. Upon 
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stimulation with Rv2660 and Rv2659 antigens, frequencies of proliferating 
CD4+ T cells were higher in the LTBI group for all cytokine-producing subsets, 
except for the total IL-2+ population (Figures 3.7A-B, right panels, 
respectively). In addition, Rv2660 and Rv2659 induced more polyfunctional 
(co-expression of IFN-γ+, TNF-α+ and IL-2+ in the same cell) cytokine 
expression in persons with LTBI, compared with TB patients. In response to 
BCG- and to ESAT-6/CFP-10, specific (proliferating) CD4+ T cells were also 
more likely to be polyfunctional in persons with LTBI, compared with patients 
with TB disease (Figure 3.7C-D); total IFN-γ+, total TNF-α+ and total IL-2 were 
also higher in persons with latent infection (Figures 3.7C-D, right panels). 
 
3.4.5 No difference in the proliferation and cytokine expression capacity of 
Rv2660- and Rv2659-specific CD8+ T cells between the 2 groups 
CD8+ T cell proliferation and cytokine expression in response to Rv2660 and 
Rv2659 was very low, and no difference was demonstrated between the 2 
groups (Figures 3.8A-B). However, persons with LTBI had greater frequencies 
of CD8+ T cells that proliferated in response to ESAT-6/CFP10 and BCG, 
compared with frequencies in patients with TB disease; the proliferating cells 
were also more likely to be polyfunctional in persons with LTBI (Figures 3.8C-
D).  
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Figure 3.8. Comparison of CD8+ T cell proliferation and intracellular cytokine 
expression in individuals with LTBI and TB disease. CD8+ T cell antigen-specific 
proliferation upon stimulation with Rv2660 (A), Rv2659 (B), BCG (C) and ESAT-6/ CFP-10 
(D), detected by gating on Oregon Greenlow CD8+ T cells. Frequencies of CD8+ T cell cytokine 
expression profiles; IFN-γ+TNF-α+IL2+, Total IFN-γ+, Total TNF-α+ and Total IL-2+, of 
proliferating cells following incubation of PBMC with antigens (A-D), and detected by 
intracellular cytokine staining. The medians are represented by the black horizontal bars. The 
Mann-Whitney U test was used to assess between the 2 groups. LTBI n = 23, TB n = 18 
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3.4. Discussion 
Mathematical modelling has indicated that an effective post-infection vaccine 
that targets latently infected individuals would have a dramatic impact on the 
TB epidemic (Abu-Raddad et al., 2009). Our study suggests that Rv2660 and 
Rv2659 are good antigenic candidates for inclusion in such a vaccine; we 
show that T cells of persons with LTBI preferentially recognise these two 
latency associated antigens, compared with T cells from patients with TB 
disease. This is the first clinical report of human immune recognition of the 
starvation stimulon gene products, Rv2660 and Rv2659.  
 
Interestingly, the same pattern of preferential recognition in LTBI, compared 
with TB disease, was observed for the crude mycobacterial antigens BCG, 
PPD, and the immunodominant early antigens ESAT-6/ CFP-10 and TB10.4 
(data for PPD and TB10.4 not shown). In agreement with our findings, Schuck 
et al recently reported higher T cell responses upon stimulation of PBMC with 
PPD and ESAT-6/ CFP10, and with other latency antigens such as Rv1733 
and Rv0140 in individuals with LTBI, compared with TB patients (Schuck et 
al., 2009). This decreased T cell response in peripheral blood may result from 
migration of specific T cells to the lung during active disease (Tully et al., 
2005) or may relate to a preferential expression of Rv2660 and Rv2659 during 
latency. Alternatively, aberrant immune regulation during disease, mediated 
by regulatory T cells (Schuck et al., 2009), anti-inflammatory cytokines such 
as IL-10 and TGF-β (Fiorenza et al., 2005; Guyot-Revol et al., 2006), or TH2 
cytokines like IL-4 and IL-13 may be responsible for the differences noted 
(Ordway et al., 2005). Our observation that T cells from patients with TB 
disease were strikingly less likely to survive in a 6-day culture, compared with 
T cells from persons with LTBI, suggest that T cell exhaustion may also be 
responsible for lower responses in the diseased group. In chronic infections 
such as HIV and CMV, a persistently high antigenic load drives specific T cell 
exhaustion and dysfunction (Barber et al., 2006; Day et al., 2006). These cells 
upregulate markers like PD-1, and are more prone to apoptosis (van 
Grevenynghe et al., 2008). We postulate that this also occurs during active TB 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 62 
disease. We have recently shown that PD-1 expression is increased on M.tb-
specific CD4+ T cells in TB diseased patients, compared to persons with LTBI 
(C. Day, unpublished observations). The aforementioned differences in 
responses between LTBI and TB diseased individuals are depicted in a 
review by Kaufmann et al, and might partly explain the disparate clinical 
outcome (Figure 3.9) (Kaufmann and McMichael, 2005; Kaufmann, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. T cells in the context of granuloma formation and maintenance. Upper part: 
Immune responses that successfully contain M.tb within a granuloma. Lower part:  
Breakdown of protective immunity due to suppression or exhaustion leading to the 
development of caseous granuloma followed by bacterial dissemination. (From Kaufmann et 
al 2010, J. Internal Medicine) 
 
Recent advances in imaging have led to the observation that granulomatous 
lesions in persons with LTBI reflect a spectrum of differential ability to support 
or suppress the persistence of viable bacteria (Barry et al., 2009). This 
spectrum is supported by our data of similar preferential recognition of 
latency-associated and immunodominant antigens in persons with LTBI, 
compared with active TB. A post-exposure vaccine would thus ideally contain 
both immunodominant and latency-associated antigens, respectively, to target 
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replicating or persisting bacteria in progressing lesions and dormant bacteria 
in successful lesions.  
 
LTBI individuals had elevated frequencies of TH1 cytokine expression among 
proliferating CD4+ T cells, compared with those in TB patients. The pattern of 
cytokine production also differed: specific T cells from persons with LTBI were 
more likely to be “polyfunctional”, i.e., able to co-express IFN-γ, TNF-α and IL-
2. This characteristic has been proposed to be associated with long-term 
memory and efficient protection against intracellular infections like M.tb 
(Makedonas and Betts, 2006; Forbes et al., 2008; Seder et al., 2008; 
Lindenstrom et al., 2009). We therefore propose that robust polyfunctional 
responses to latency and immunodominant antigens may prevent LTBI 
individuals from progressing to TB disease. Therefore, because latency 
associated antigens would not be expressed in early stages of infection, T 
cells directed to these antigens may not be subjected to regulation by the 
established effector and/or regulatory T cells primed in the earlier stages of 
infection. 
 
CD8+ T cell responses to immunodominant antigens could be detected, and 
were higher in LTBI compared with TB disease; however, CD8+ T cell 
responses to Rv2659 and Rv2660 were very low, which may be the reason 
why no difference could be demonstrated between the participant groups. We 
cannot exclude that differences in antigen presentation between CD4+ and 
CD8+ T cells could have affected these results. 
 
A limitation of our study was the different age and gender ratios in the LTBI 
and TB groups. Ideally, participants in such groups should be matched for 
these co-variates. However, given the fact that only polyfunctional CD4+ T 
cells and no other outcomes were different in males and females, the unequal 
gender ratio did not markedly confound our results.  
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The prophylactic TB subunit vaccines currently under development are almost 
exclusively based on early or immunodominant antigens secreted by 
replicating M.tb, which are recognized in the first stage of infection, and are 
designed as BCG boosters to prevent primary TB disease (Andersen, 2007a). 
The addition of latency associated antigens to well-established prophylactic 
vaccines (i.e., the vaccine candidates under clinical testing today) have been 
suggested as the basis for a future generation of multi-stage TB vaccines with 
activity against all stages of infection (Andersen, 2007a). Our finding of 
immune recognition of these novel antigens in persons with LTBI has 
contributed to the development of a new subunit vaccine, H56, by the Statens 
Serum Institut. This vaccine is based upon the H1 subunit vaccine currently in 
clinical trials, which contains Ag85B and ESAT-6 (van Dissel et al., 2010) and 
the Rv2660 antigen, and will be the first to enter clinical trials as a post-
infection vaccine candidate. We hypothesize that inducing robust T cell 
responses to latency antigens may enhance immunological control of latent 
TB, and prevent reactivation. Much more research is needed to determine 
whether candidate latency-, starvation-, or resuscitation-associated antigens 
other than Rv2659 or Rv2660 would be needed for inclusion in an optimal 
post-infection vaccine.  
Ultimately, a combined strategy that includes primary vaccination with a live 
attenuated vaccine followed by a multi-stage subunit boost vaccine; may have 
maximum impact on the TB epidemic.  
 
3.5 Contributions 
Lerisa Govender designed the experiments, conducted the laboratory and 
data analysis, and wrote this chapter under supervision of Prof. W.A. 
Hanekom, Dr. B. Abel, Jane Hughes and other members of SATVI laboratory. 
Gerhard Walz and others from Stellenbosch University provided the PBMC 
from the TB diseased group. 
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4.1. Abstract 
Antigen-specific proliferation is a critical function of memory T cells that is 
often utilized to measure vaccine immunogenicity and T cell function. We 
proposed that measurement of intracellular expression of the nuclear protein, 
Ki67, could reliably assess specific T cell proliferation in vitro.  
Ki67 was expressed in CD4+ and CD8+ T cells that had undergone in vitro 
proliferation after 6-day culture of human whole blood or PBMC with antigens. 
T cells cultured with no antigen for 6 days did not express Ki67. When 
compared to current flow cytometry based proliferation assays, Ki67 detected 
proliferating cells with greater sensitivity than BrdU incorporation, whereas its 
sensitivity was similar to dye dilution of Oregon Green (OG), a CFSE 
derivative. Overall, the magnitude and cytokine expression profile of 
proliferating T cells detected by Ki67 expression correlated strongly with T 
cells detected with BrdU or OG. The intra-assay variability of Ki67 proliferation 
was 2-3% for CD4+ T cells, and 10-16% for CD8+ T cells. Finally, we 
demonstrate that the Ki67 assay detects tetanus toxoid-specific CD4+ T cell 
proliferation after infant vaccination with tetanus toxoid (TT). 
Overall our data suggest that intracellular Ki67 expression provides a specific, 
quantitative and reproducible measure of antigen-specific T cell proliferation in 
vitro.  
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4.2. Introduction 
Proliferation and clonal expansion of antigen-specific T cells are critical 
functions for mediating protective immunity and immunological memory 
(Rosenberg et al., 1997; Combadiere et al., 2004). Previously, the most 
widely used method for detection of antigen-specific T cell proliferation has 
involved incorporation of 3H-thymidine into DNA of dividing cells (Payan et al., 
1983; Marchant et al., 1999). This technique has largely been replaced by 
flow cytometric assays of proliferation. Examples include fluorescent dye 
dilution assays, using CFSE or its derivative, Oregon Green (OG) (Magg and 
Albert, 2007; Wallace et al., 2008; MacMillan et al., 2009), and assays that 
detect the DNA intercalating agent, 5-bromo-2’-deoxyuridine (BrdU), detected 
by fluorochrome-conjugated antibody staining (Dolbeare et al., 1983; Houck 
and Loken, 1985; Rosato et al., 2001). The advantages of these assays are 
that they allow co-staining with other markers, enabling delineation of cellular 
sub-populations according to phenotype (Precopio et al., 2007) and functional 
characteristics, such as cytokine production (Lyons, 2000; Bachmann et al., 
2005; Davids et al., 2006).  
 
Ki67 is a nuclear protein that plays a role in the regulation of cell division. This 
marker has been used extensively in cancer biology to indicate tumour cell 
proliferation (Gerdes, 1990; Scholzen and Gerdes, 2000). The protein is 
expressed during all active phases of cell division, but is absent in quiescent 
cells and during DNA repair (Gerdes et al., 1984). Intracellular Ki67 
expression directly ex vivo, or after in vitro cell culture, has been used to 
measure specific T cell responses induced by vaccination (Stubbe et al., 
2006; Cellerai et al., 2007; Miller et al., 2008), or turnover of these cells in 
individuals with chronic viral infections, such as HIV infection (Sachsenberg et 
al., 1998; Doisne et al., 2004).  
 
In this study, we show that Ki67 expression in T cells is a specific and 
quantitative indicator of proliferation, and that results are comparable to those 
when proliferation is measured by other methods. We also show that 
measurement of Ki67 may be applied to longitudinal monitoring of vaccine-
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specific T cell responses. Overall, the Ki67 assay offers a reliable, versatile 
and simple method for detection of antigen-specific T cell proliferation. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 69 
4.3. Materials and methods 
4.3.1 Study participants 
Healthy adult donors were recruited at the Institute of Infectious Disease and 
Molecular Medicine, University of Cape Town. Healthy, 18-month old toddlers 
were recruited at the South African Tuberculosis Vaccine Initiative clinic sites 
in the Western Cape, South Africa, before, and 11-13 days after their routine 
18-month vaccination against tetanus toxoid (TT). Enrolled toddlers had 
received all routine childhood vaccinations as set out by the WHO Expanded 
Programme on Immunisation. Heparinised venous blood from adults and 
toddlers was collected into BD Vacutainer CPT tubes (BD Biosciences) and 
immediately processed as outlined below. Participation of all participants was 
in accordance with the Declaration of Helsinki, the US Department of Health 
and Human Services guidelines, and good clinical practice guidelines. This 
included protocol approval by the Research Ethics Committee of the 
University of Cape Town, and written informed consent by all adults or 
parents of the toddlers.  
 
4.3.2 Six-day Whole blood BrdU incorporation assay 
Performed as described in chapter 2 (section 2.1.3) with the following 
changes: Antigens were used at the following final concentrations: 1 x 
105cfu/mL Danish BCG (Danish strain 1331; Statens Serum Institut), 1µg/mL 
TB10.4 protein (ki dly provided by Tom Ottenhoff, Leiden University, Leiden, 
Netherlands), 2µg/mL M. tuberculosis purified protein derivative (PPD, 
Statens Serum Institut) and 0.16IU tetanus toxoid (Tetavax, Sanofi Pasteur). 
On day 6, cells were harvested with 2mM EDTA (Sigma-Aldrich) and red 
blood cells lysed. White cells were stained with a viability dye (ViViD, 
LIVE/DEAD Fixable Violet Dead Cell Stain Kit, Invitrogen), fixed in BD FACS 
Lysing Solution (BD Biosciences) according to the manufacturerʼs instructions 
and cryopreserved until analysis. 
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4.3.3 PBMC isolation and the OG assay 
Performed as described in chapter 2 (section 2.1.5) with the following 
changes: Freshly isolated cells were either incubated with medium or 
stimulated with 1 x 105cfu/mL Danish BCG, 0.5µg/mL PPD, 1µg/mL TB10.4 
protein or 0.05µg/mL staphylococcal enterotoxin B (SEB, positive control, 
Sigma-Aldrich), for 6 days at 37oC with 5% CO2.  
 
4.3.4 Antibodies and flow cytometry 
Fixed, cryopreserved cells were thawed, washed with PBS and permeablised 
with Perm/Wash Solution for 10 minutes. The following monoclonal antibodies 
were used for phenotypic and/or intracellular cytokine staining: CD3-QDot 605 
(UCHT1), CD4-PerCP (SK3), CD8-PerCPCy5.5 (SK1), Ki67-PE (B56), IFN-γ-
Alexa Fluor 700 (B27), TNF-α-PECy7 (MAb11), IL-2-APC (MQ1-17H12), anti-
BrdU-FITC (B44). All antibodies were from BD Biosciences except for CD3-
QDot 605, which was from Invitrogen. Samples were acquired on a BD LSRII 
flow cytometer (BD Biosciences, San Jose, CA). Boolean gating was applied 
to generate combinations of cytokine expressing CD4+ and CD8+ T cell 
subsets. 
 
4.3.5 Data analysis 
Data were analysed with FlowJo software v.8.8.6 (Treestar Inc.), Pestle v 
1.6.2 and Spice v 4.3.2 software. Statistical analyses were calculated using 
GraphPad Prism v 5.0. 
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4.4. Results 
4.4.1 Ki67 is a specific marker of in vitro lymphoproliferation 
Ki67 is expressed by all cells undergoing cycling (Lopez et al., 1991; 
Scholzen and Gerdes, 2000). Since a subset of peripheral blood lymphocytes 
undergoes homeostatic proliferation in vivo, we investigated the kinetics of 
Ki67 expression by cultured T cells over 6 days. Whole blood was either 
cultured in the absence of antigen, or in the presence of purified protein 
derivative (PPD) or the co-stimulatory antibodies, anti-CD3 and anti-CD28 
(αCD3/αCD28), and expression of Ki67 quantified each day. Ki67 expression 
by unstimulated CD4+ T cells was low (median, 0.62%) on day 1 and, by day 
6 had decreased to less than 0.1% of CD4+ T cells (median, 0.08% on day 6, 
Figure 4.1A). Upon PPD stimulation, specific Ki67 expression, above levels in 
unstimulated cells, was detected between days 2 and 4, and this expression 
peaked on day 6 (Figure 4.1A and B). Markedly increased expression of Ki67 
was already seen after 1 day upon polyclonal T cell stimulation with 
αCD3/αCD28. Ki67 expression peaked on day 3 after which the frequency of 
Ki67+ CD4+ T cells gradually decreased (Figure 4.1A and C). 
Next, we quantified antigen-specific CD4+ T cell proliferation by Ki67 detection 
in whole blood from 15 healthy donors after 6-day culture with no antigen, or 
with PPD. All donors had undetectable or very low frequencies (median, 
0.07%) of Ki67+ CD4+ T cells in unstimulated blood. Upon PPD stimulation, 
however, frequencies of Ki67+ CD4+ T cells were readily detected in all donors 
at a median of 46.1% (Figure 4.1D). 
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Figure 4.1. Ki67 is a specific marker of in vitro lymphoproliferation. Whole blood from 
healthy donors was incubated with the indicated antigens and Ki67 expression quantified on a 
daily basis over 6 days. (A) Representative example showing the frequencies of Ki67 
expression by CD4+ T cells after incubation of whole blood with medium only (Uns), PPD or 
αCD3/αCD28 over 6 days. Dotplots were gated on live, CD3+ CD4+ lymphocytes. Ki67+ CD4+ 
T cell frequencies after PPD stimulation (B) or αCD3/αCD28 stimulation (C) in 4 donors. Data 
are expressed as a percentage of the maximum response. The frequency of Ki67+ CD4+ T 
cells is indicated in each plot. (D) Frequencies of Ki67 expressing CD4+ T cells in whole blood 
from 15 donors after 6-day culture with medium only (Uns) or PPD. (E) Frequencies of Ki67+ 
CD4+ T cells in PBMC from 14 donors. Differences were calculated using the Wilcoxon 
matched pairs test.  
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We also determined Ki67-based measurement of antigen-specific T cell 
proliferation in PBMC. Again, Ki67 expression identified in vitro CD4+ T cell 
proliferation; frequencies of Ki67+ cells after PPD stimulation exceeded those 
in unstimulated PBMC in all donors, at a median of 21.7% (Figure 4.1E). 
These data suggest that in long-term PBMC or whole blood culture with 
antigen, Ki67 expression is upregulated in CD4+ T cells undergoing in vitro 
proliferation. 
 
4.4.2 Comparison of Ki67 expression with BrdU and Oregon Green assays 
Next, we compared results obtained from a Ki67-based proliferation assay 
with those obtained using more traditional proliferation assays. We compared 
proliferation in whole blood measured by Ki67 expression with that in whole 
blood measured by BrdU incorporation, and in PBMC measured by Ki67 
expression and dye dilution of OG (Figures. 4.2 and 4.3). 
BrdU is incorporated into cells undergoing DNA synthesis, and is typically 
added during the last 2 to 24 hours of a proliferation assay; in this study we 
always added BrdU for the last 5 hours of the 6-day culture. Compared with 
the frequency of BrdU+ cells the frequency of Ki67+ CD4+ T cells was higher 
after whole blood stimulation with PPD or TB10.4 protein (Figure. 4.2A-C). 
Importantly, all BrdU+ cells co-expressed Ki67. 
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Figure 4.2. Comparison of the Ki67 proliferation assay with the BrdU proliferation 
assay. (A) Representative dotplots showing Ki67 versus BrdU expression by CD4+ T cells in 
whole blood. Dotplots are gated on live, CD3+ CD8- lymphocytes. Frequencies of (B) PPD and 
(C) TB10.4 protein specific CD4+ T cell proliferation as detected by Ki67 expression (top left) 
or BrdU incorporation (bottom right) (n=15). CD4+ T cells are defined as CD3+CD8- T cells 
(see methods: Data analysis). Differences were calculated using the Wilcoxon matched pairs 
test. 
 
The OG assay requires uniform labelling of cells prior to long-term culture. In 
contrast to results from the BrdU assay, the OG and Ki67 assays yielded 
remarkably similar frequencies of proliferating, specific T cells; Ki67+ and 
OGlow CD4+ T cell frequencies were not different in PPD or TB10.4-stimulated 
PBMC (Figure. 4.3A-C). 
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Figure 4.3. Comparison of the Ki67 proliferation assay with the Oregon Green 
proliferation assay. (A) Representative dotplots showing Ki67 and dye dilution of Oregon 
Green by CD4+ T cells in PBMC. Dotplots are gated on live, CD3+ CD8- lymphocytes. 
Frequencies of (B) PPD- and (C) TB10.4-specific CD4+ T cell proliferation as detected by 
Ki67 expression (top right) or dye dilution of Oregon Green (OGlow) (bottom left) in 14 donors. 
CD4+ T cells are defined as CD3+CD8- T cells (see methods: Data analysis). Differences were 
calculated using the Wilcoxon matched pairs test. 
 
Frequencies of Ki67+ CD4+ T cells correlated strongly with BrdU+ CD4+ T cell 
frequencies (PPD: r = 0.8036, p=0.0003; TB10.4 protein: r=0.9308, p<0.0001) 
(Figure 4.4A and B). Similarly, a strong correlation was found between 
frequencies of antigen-specific Ki67+ and OGlow CD4+ T cells (PPD: r=0.9868, 
p<0.0001; TB10.4 protein: r=0.9473, p<0.0001) (Figure 4.4C and D). 
 
These data show that intracellular Ki67 expression allows quantitative 
measurement of antigen-specific T cell proliferation, and that frequencies of 
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proliferating T cells detected by Ki67 expression correlate strongly with 
frequencies detected with conventional proliferation assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Correlation between Ki67+ CD4+ T cell expression and BrdU incorporation or 
dye dilution of Oregon Green. Whole blood was incubated with (A) PPD or (C) Tb10.4 
protein for 6 days (n=15). PBMC were incubated with (B) PPD or (D) TB10.4 protein for 6 
days (n=14). 
 
4.4.3 Cytokine expression profiles of proliferating CD4+ T cells 
The functional capacity of T cells that have expanded during the 6-day culture 
may be assessed by short-term polyclonal re-stimulation with PMA and 
ionomycin on day 6. This induces cytokine production, which can be 
measured by intracellular staining. We compared expression of IFN-γ, IL-2 
and TNF-α by Ki67+ CD4+ T cells with expression of these cytokines in BrdU+ 
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or OGlow CD4+ T cells. When Ki67 and BrdU assay results were compared, 
similar expression of IFN-γ and TNF-α was observed in proliferating CD4+ T 
cells. BrdU+ CD4+ T cells yielded higher proportions of IL-2+ cells than Ki67+ 
CD4+ T cells but these differences were small (Figure 4.5A and B). Similar 
expression profiles of IFN-γ, IL-2 and TNF-α were observed when comparing 
Ki67+ and OG dilution (Figure 4.5C and D). 
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Figure 4.5. Cytokine expression profiles of proliferating CD4+ T cells. Whole blood (A-B) 
or PBMC (C-D) were cultured for 6 days with no antigen or PPD. On day 6, cells were 
restimulated with PMA and ionomycin for 4 hours in the presence of Brefeldin A to detect 
cytokine expression by proliferating T cells. Representative dotplots of the cytokine 
expression profiles of (A) Ki67+ (top left) or BrdU+ (bottom right) CD4+ T cells and (C) Ki67+ 
(top right) or OGlow (bottom left) CD4+ T cells. (B) Proportions of BrdU+, Ki67+ or Ki67+BrdU- 
CD4+ T cells expressing IFN-γ, IL-2 or TNF-α (n=15). (D) Proportions of Ki67+ or OGlow CD4+ 
T cells expressing IFN-γ, IL-2 or TNF-α (n=14). 
 
4.4.4 Intra-assay variability of Ki67 proliferation assay 
To test the reproducibility of the Ki67 proliferation assay, we performed 5 
proliferation assays per donor on whole blood from 3 healthy adult volunteers. 
Intra-assay CV values for PPD-specific Ki67+ CD4+ T cells were ≤ 4,33% and 
for Ki67+ CD8+ T cells ≤16,14%. Even lower CV values were observed for 
PHA-stimulated blood (Table 1). This indicates that the Ki67 proliferation 
assay is highly reproducible. 
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Table 1. Intra-assay CV values for frequencies of Ki67 expression by T 
cells after PPD or PHA stimulation. 
PPD stimulation  
 Donor 1 Donor 2 Donor 3 
subset Ki67+CD4+ Ki67+CD8+ Ki67+CD4+ Ki67+CD8+ Ki67+CD4+ Ki67+CD8+ 
Mean 66.2 10.31 79.82 8.3 62.79 3.03 
SD 1.88 1.66 1.46 0.86 1.33 0.34 
CV 2.84 16.14 1.83 10.42 2.12 11.17 
       
PHA stimulation 
 Donor 1 Donor 2 Donor 3 
subset Ki67+CD4+ Ki67+CD8+ Ki67+CD4+ Ki67+CD8+ Ki67+CD4+ Ki67+CD8+ 
Mean 94.5 91.26 94.7 91.7 76.65 74.54 
SD 0.87 1.14 0.81 1.11 3.32 2.4 
CV 0.92 1.25 0.86 1.21 4.33 3.21 
 
4.4.5 Monitoring of vaccination-induced T cell proliferation 
It is well established that vaccination-induced T cell proliferation results in 
increased in vivo and, thus, ex vivo expression of Ki67 (Cellerai et al., 2007; 
Miller et al., 2008). To determine whether these “background” expression 
levels of Ki67 affect the specificity of detecting antigen-specific proliferation of 
T cells in vitro, we assessed 6-day antigen-specific T cell proliferation before 
and 11-13 days after tetanus toxoid (TT) vaccination of healthy, 18-month old 
toddlers (Figure 4.6). This post-vaccination time point was selected because it 
coincides with the peak TT-specific CD4+ T cell response in healthy adults 
(Cellerai et al., 2007). 
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Figure 4.6. Diagram illustrating the strategy for monitoring of tetanus toxoid vaccine-
specific responses by Ki67 whole blood assay.  
 
The frequency of in vitro proliferating, Ki67+ CD4+ T cells observed pre-
vaccination was low (median, 0.15%). After vaccination, TT-specific CD4+ T 
cell proliferation increased markedly (median, 3.77%, Figure 4.7A and B). To 
control for possible non-specific up-regulation of Ki67 after TT vaccination, we 
also quantified BCG-specific T cell proliferation pre- and post- vaccination. 
Frequencies of BCG-specific Ki67+ CD4+ T cells before and after TT 
vaccination were not different (Figure 4.7A and C). We also compared the 
relative TT-induced increase in T cell proliferation between TT and BCG-
specific Ki67+ CD4+ T cells. TT vaccine boosting of TT-specific Ki67+ CD4+ T 
cells was significantly higher than BCG-specific Ki67+ CD4+ T cells (Figure 
7D). 
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Figure 4.7. Monitoring of vaccination-induced T cell proliferation. (A) Dotplots showing 
Ki67 expression by CD4+ T cells from a representative 18 month old toddler before (pre-TT) 
and after TT vaccination (post-TT). Dotplots are gated on live, CD3+ lymphocytes. Values in 
each dotplot represent the frequency of  Ki67+ T cells within the CD3+CD8- T cell population. 
Frequencies of (B) TT-specific and (C) BCG-specific CD4+ T cells pre- and post-TT 
vaccination in  11 toddlers. CD4+ T cells are defined as CD3+CD8- T cells (see methods: Data 
analysis). (D) Relative increase in TT-specific or BCG-specific CD4+ T cells pre- and post-TT. 
Lines represent the medians. Differences were calculated using the Wilcoxon matched pairs 
test.  
 
To further examine the effects of vaccination-induced CD4+ T cell proliferation 
on the Ki67 proliferation assay, we quantified Ki67 expression directly ex vivo 
in whole blood from toddlers before and 11-13 days after TT-vaccination. High 
ex vivo frequencies of Ki67+ CD4+ T cells were readily detected before and 
after vaccination in all toddlers (Figure 4.8A-B). Importantly, after 6 days of 
culture with no antigen, Ki67 expression decreased markedly in all toddlers to 
background levels (Figure 4.8A-B). 
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Figure 4.8. High ex vivo frequencies of Ki67+ cell are decreased after 6 days in culture 
without antigen. (A) Dotplots illustrating frequencies of Ki67+ CD4+ T cells in whole blood 
directly ex vivo or after culture in the absence of antigen (Uns) for 6 days. Values in each 
dotplot represent the frequency of  Ki67+ T cells within the CD3+CD8- T cell population. (B) 
Frequencies of  Ki67+ CD4+ T cells directly ex vivo or after culture for 6 days with medium 
(n=11). CD4+ T cells are defined as CD3+CD8- T cells (see methods: Data analysis). 
Differences were calculated using the Wilcoxon matched pairs test.  
 
These data suggest that in vivo CD4+ T cell proliferation does not interfere 
with the specificity of the Ki67 proliferation assay. This assay is therefore 
sensitive for detecting antigen-specific in vitro CD4+ T cell proliferation.  
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4.5. Discussion 
Proliferation is a commonly measured indicator of T cell function. We 
assessed intracellular Ki67 expression as a marker of in vitro proliferation in 
whole blood or PBMC-based assays.  We show that the Ki67 assay provides 
an alternative approach to measuring antigen-driven T cell proliferation, and 
found that results obtained were very similar to those generated by commonly 
used proliferation assay systems.  
The development of fluorescent dyes and tracking markers has enabled 
combined analysis of antigen-specific T cell proliferation, phenotyping and 
cytokine expression by flow cytometry (Johannisson and Festin, 1995; Mehta 
and Maino, 1997; Lyons and Doherty, 2004; Wallace et al., 2008). To date, 
whole blood BrdU and PBMC dye dilution assays have been the preferred 
flow cytometry based methods to assess lymphocyte proliferation. In 
comparison, Ki67 expression identified approximat ly double the frequency of 
proliferating CD4+ T cells detected by BrdU incorporation. Incubation of cells 
with BrdU is limited to 24 hours or less because incorporated BrdU inhibits 
cell cycle progression. Therefore a major limitation of the BrdU assay is that 
only cells that have progressed through the S-phase during this short 
incubation period may be detected. In contrast, cells express Ki67 in all active 
phases of the cell cycle. Therefore, Ki67 appears to be a more sensitive 
marker for the detection of rare T cell responses, and may reflect the extent of 
in vitro antigen-specific proliferation more accurately than BrdU incorporation.  
Cellular proliferation in PBMC samples is routinely evaluated by dye dilution 
methods, using CFSE or derivatives such as OG (Robinson and Amara, 
2005). A recent non-human primate study has proposed measurement of in 
vitro proliferation by the combined analysis of Ki67 and side scatter properties 
of cells (Shedlock et al., 2010). The authors demonstrate a correlation 
between this assay and the CFSE dilution assay. In this study, we show that 
the proliferation events detected by loss of OG dye are virtually identical to the 
Ki67+ events. From this we reasoned that Ki67 expression is an accurate 
measure of CD4+ and CD8+ T cell proliferation as only cells that have 
completed cycling display a decrease in OG fluorescence intensity. 
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Limitations of many protein reactive dye compounds include cellular toxicity 
(Last'ovicka et al., 2009; Shedlock et al., 2010) and sensitivity to pH and light 
(Wallace et al., 2008). The Ki67 proliferation assay requires no incubation or 
washing steps prior to or during the culture, and exposure of cells to toxic 
compounds is eliminated. Additionally, since labelling of cells is not required 
before antigen stimulation, detection of Ki67 by flow cytometry can be 
performed on antigen-stimulated cells after cryopreservation. A limitation of 
Ki67 as a proliferation marker is its inability to resolve the number of 
proliferation cycles that cells have undergone, as can be done with dye 
dilution assays (Parish, 1999; Lyons and Doherty, 2004). Enumeration of cell 
cycles enables calculation of the original precursor frequency of specific cells, 
since the number of cells and their respective number of divisions are known 
(Givan et al., 1999).  
Monitoring vaccine-induced T cell proliferative potential is important for 
determining vaccine take, memory function and long-term persistence of 
vaccine-specific responses. Previous studies have quantified Ki67 expression 
directly ex vivo as a measure of the vaccine-induced proliferative response 
(Miller et al., 2008), or in combination with activation markers to identify 
antigen-specific T cells (Stubbe et al., 2006). To detect increases in the 
expression of Ki67, these studies relied on low-level Ki67 expression before 
vaccination in healthy adults. Direct ex vivo detection of antigen-specific Ki67 
expression may thus be challenging in individuals with high levels of in vivo T 
cell proliferation – such as those resulting from recent vaccinations or 
infections. We observed high ex vivo frequencies of Ki67+ CD4+ T cells in 
toddlers, suggesting elevated levels of in vivo T cell turnover. This turnover is 
likely to be driven by routine childhood vaccinations and exposure to 
infections, common in this age group. Whole blood culture in the absence of 
antigen reduced Ki67 expression to barely detectable levels by day 6, 
presumably due to cells reverting to a quiescent state. Therefore, this 6-day 
assay proved to be sufficiently specific and sensitive for the identification of 
rare, antigen-specific CD4+ T cells following vaccination in the context of high 
ex vivo frequencies of Ki67+ T cells. 
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Overall, our data show that outcomes of the Ki67 assay correlate strongly with 
current flow cytometry based whole blood and PBMC proliferation assays. 
This assay is highly reproducible, versatile, and presents several practical 
advantages over current techniques. We propose Ki67 as a marker for 
quantifying antigen-specific CD4+ and CD8+ T cell proliferation, and utilising 
this assay to monitor T cell responses in large field studies or paediatric 
studies based on limited blood volumes.  
 
4.6 Contributions  
Andreia Soares and Lerisa Govender designed the experiments, conducted 
the laboratory and data analysis, and wrote this chapter under the supervision 
of Prof. W.A. Hanekom, Dr T.J. Scriba and Dr. B. Abel, and other members of 
SATVI laboratory. 
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Chapter 5: General Discussion 
Nearly 130 years have elapsed since the discovery of M.tb, yet TB disease 
still remains a major cause of morbidity and mortality in many developing 
countries. Research into new, safer and more effective vaccine regimes and 
strategies to combat the scourge of TB are ongoing. Since one third of the 
worldʼs population is latently infected with M.tb, a post-infection vaccine that 
would prevent reactivation of M.tb infection in these people is urgently 
needed.  
 
The selection of antigens for incorporation into novel vaccines is challenging, 
and much emphasis is placed on preliminary findings from in vitro models of 
M.tb, which attempt to simulate in vivo infection. However, prior to inclusion of 
potential antigens into a vaccine, antigen recognition should be assessed in 
appropriate clinical studies. 
 
The first study in this thesis provides insight into candidate antigens for a 
potential post-infection TB vaccine. We demonstrate that Rv2660 and Rv2659 
are promising antigens for such a vaccine, since greater immune recognition 
and associated CD4+ T cell effector function was observed in M.tb latently 
infected individuals compared with TB diseased patients. Indeed, based on 
initial findings at SATVI, Rv2660 was incorporated into a post-infection 
subunit vaccine, H56, which includes Ag85B and ESAT-6, and has already 
entered preclinical trials. Preclinical testing of this vaccine in a post-infection 
murine model has shown that vaccination with H56 decreases lung CFUs 
compared with only BCG vaccination, after challenge with M.tb (Peter 
Andersen, personal communication, 2010). Ultimately, this post-infection 
vaccine would only be considered a viable option if immune recognition to 
possible candidate antigens, such as Rv2660 and Rv2659 are shown in 
human studies. For this reason it is vital that candidate latency associated 
M.tb antigens initially be screened in human populations to assess the 
breadth of immune recognition and for potential inclusion in post-infection 
vaccines. Once antigens have been incorporated in a vaccine, the safety and 
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immunogenicity of the vaccine would be tested in preclinical settings. Multiple 
clinical trials have to be concluded before the vaccine can be introduced to the 
public. Phase I vaccine trials are designed to assess adverse advents and 
immunogenicity as a secondary outcome starting with healthy adults then 
adolescents and children. This will be followed by Phase II and III trials, in 
which the vaccine safety, immunogenicity and efficacy are assessed in 
latently infected individuals who are the target population for the post-infection 
vaccine. 
 
To assess novel TB vaccines, it is imperative that appropriate assays are 
optimised to generate efficient, sensitive and reliable results. Hence the 
second study of this thesis addressed the optimal and efficient measurement 
of T cell vaccine-specific responses using Ki67 as marker of antigen-specific 
lymphoproliferation. We demonstrate that Ki67 expression in T cells is a 
specific and quantitative indicator of proliferation. Importantly, since this assay 
is not labour intensive and requires small volumes of blood, it can be used to 
study neonates where only limited blood volumes can be collected.  
 
There were 3 major limitations of the study. Firstly, the study investigating 
Rv2660 and Rv2659 as candidate antigens for a potential post-infection 
vaccine could have been strengthened by LTBI and TB disease cohorts that 
were age and gender matched; this was not possible for this study due to the 
availability of cryopreserved PBMC from select TB patients at the time of 
study commencement. Secondly, the differential use of fresh and 
cryopreserved PBMC in the cohorts could have affected results, as freshly 
isolated PBMC allow for greater sensitivity in measuring immune responses. 
Finally, the Ki67 assay could be further optimised by using cryopreserved 
PBMCs, rather than fresh PBMC or whole blood. Preliminary results from our 
group have indicated that long-term cryopreservation may affect background 
levels of Ki67 expression – this needs to be evaluated formally. 
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There are many significant challenges in the field of TB vaccine research, 
including inadequate advocacy and funding, few and expensive optimal 
preclinical animal models, lack of validated immune correlates of vaccination-
induced protection, difficulties in making accurate and reliable diagnosis of TB 
disease, the endpoint of phase IIb and III trials. In addition, there is a lack of 
standardisation of immunological assessment across trials, and no candidate 
vaccines in trials that are designed to specifically prevent progression of M.tb 
infection to TB disease. We propose that results presented in this thesis will 
address the latter 2 issues, through description of a practical assay that may 
be used in vaccine trials, and by confirming that 2 new latency-associated 
antigens are recognised in human populations,  
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6. Appendix 
Alternative lysing solution (Ammonium chloride lysing solution)  
All chemicals supplied by: Sigma Aldrich 
150mM NH4Cl 
Cat.No: A9434 
10mM  KHCO3 
Cat.No: P9144 
1mM EDTA  
Cat. No: E6511 
Ingredients per litre distilled water 
 
BCG (Mycobacterium bovis bacillus Calmette-Guerin Danish 1331 
strain) 
Supplier: Statens Serum Institut 
Cat. No.: 4203166 
 
BrdU  
Supplier: Sigma Aldrich 
Cat. No.: 16880 
 
Brefeldin-A  
Supplier: Sigma Aldrich 
Cat. No: B-7651  
 
Cryo-solution 
This will finally consist of 20% DMSO in FCS in RPMI.  
-DMSO 
Supplier: E Merck  
Cat. No: BB103234L 
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FCS 
Supplier: Adcock Ingram 
Cat. No: 14-501AIH  
 
DNase 
Supplier: Sigma Aldrich 
Cat. No: D4513  
 
ELISA coating buffer 
0.1M NaHCO3 
Supplier: Sigma Aldrich 
Cat. No: S5761 
Ingredient per litre 1X PBS, pH 8.2 
 
ELISA dilution and blocking buffer (1% BSA) 
10 g BSA  
Supplier: Boehringer Mannheim 
Cat No: 519 987 
0.3 g NaN3  
Supplier: Sigma Aldrich 
Cat. No: 08591 
Ingredients per litre 1X PBS 
 
FACS Lysing Solution  
Supplier: Scientific Group  
Cat No: B-D 349202 
 
Heat inactivated AB serum 
Supplier: Sigma Aldrich 
Cat. No: H4522 
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Ionomycin  
Supplier: Sigma Aldrich 
Cat. No: I-0634  
 
Oregon Green 
Supplier: Invitrogen 
Cat. No: 0344550  
 
Perm/Wash Buffer: 
Supplier: Scientific Group  
Cat. No.: 554723  
 
PHA  
Supplier: Bioweb 
Cat. No.: HA16 
 
PBS 
Supplier: BioWhittaker 
Cat. No: 17-517Q 
 
PMA  
Supplier: Invitrogen 
Cat. No: P-8139 
 
PPD   
Supplier: Statens Serum Institut 
Cat. No.: 2390 
 
RPMI 
Supplier: Adcock Ingram 
Cat. No: 12-702F 
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SEB 
Supplier: Sigma Aldrich 
Cat. No: S4881 
 
ViViD 
LIVE/DEAD Fixable Violet Dead Cell Stain kit  
Supplier: Invitrogen 
Cat. No: L34955 
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